@manuscripts/transform 4.3.53 → 4.4.0

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (172) hide show
  1. package/dist/cjs/jats/__tests__/jats-roundtrip.test.js +3 -3
  2. package/dist/cjs/version.js +1 -1
  3. package/dist/es/jats/__tests__/jats-roundtrip.test.js +3 -3
  4. package/dist/es/version.js +1 -1
  5. package/dist/types/jats/__tests__/utils.d.ts +1 -1
  6. package/dist/types/version.d.ts +1 -1
  7. package/package.json +22 -21
  8. package/src/errors.ts +28 -0
  9. package/src/getVersion.ts +21 -0
  10. package/src/index.ts +28 -0
  11. package/src/jats/__tests__/__fixtures__/debug-example.xml +136 -0
  12. package/src/jats/__tests__/__fixtures__/jats-abstract-no-body.xml +163 -0
  13. package/src/jats/__tests__/__fixtures__/jats-citations.xml +472 -0
  14. package/src/jats/__tests__/__fixtures__/jats-comments.xml +46 -0
  15. package/src/jats/__tests__/__fixtures__/jats-document.xml +134 -0
  16. package/src/jats/__tests__/__fixtures__/jats-example-doc.xml +1235 -0
  17. package/src/jats/__tests__/__fixtures__/jats-example-front-only.xml +26 -0
  18. package/src/jats/__tests__/__fixtures__/jats-example-full.xml +209 -0
  19. package/src/jats/__tests__/__fixtures__/jats-example-no-back.xml +156 -0
  20. package/src/jats/__tests__/__fixtures__/jats-example-no-body.xml +91 -0
  21. package/src/jats/__tests__/__fixtures__/jats-example.xml +221 -0
  22. package/src/jats/__tests__/__fixtures__/jats-fn-group.xml +60 -0
  23. package/src/jats/__tests__/__fixtures__/jats-import-no-refs.xml +1077 -0
  24. package/src/jats/__tests__/__fixtures__/jats-import.xml +1561 -0
  25. package/src/jats/__tests__/__fixtures__/jats-roundtrip.xml +133 -0
  26. package/src/jats/__tests__/__fixtures__/jats-tables-example.xml +2043 -0
  27. package/src/jats/__tests__/__fixtures__/math-fragment.xml +12 -0
  28. package/src/jats/__tests__/__snapshots__/citeproc.test.ts.snap +57 -0
  29. package/src/jats/__tests__/__snapshots__/create-article-node.test.ts.snap +65 -0
  30. package/src/jats/__tests__/__snapshots__/jats-exporter.test.ts.snap +7 -0
  31. package/src/jats/__tests__/__snapshots__/jats-importer.test.ts.snap +59605 -0
  32. package/src/jats/__tests__/__snapshots__/jats-roundtrip.test.ts.snap +18 -0
  33. package/src/jats/__tests__/citations.ts +25 -0
  34. package/src/jats/__tests__/citeproc.test.ts +195 -0
  35. package/src/jats/__tests__/create-article-node.test.ts +29 -0
  36. package/src/jats/__tests__/data/section-categories.ts +212 -0
  37. package/src/jats/__tests__/files.ts +24 -0
  38. package/src/jats/__tests__/jats-exporter.test.ts +223 -0
  39. package/src/jats/__tests__/jats-importer.test.ts +567 -0
  40. package/src/jats/__tests__/jats-roundtrip.test.ts +66 -0
  41. package/src/jats/__tests__/utils.ts +90 -0
  42. package/src/jats/exporter/citeproc.ts +265 -0
  43. package/src/jats/exporter/jats-exporter.ts +2090 -0
  44. package/src/jats/exporter/jats-versions.ts +50 -0
  45. package/src/jats/exporter/labels.ts +101 -0
  46. package/src/jats/importer/create-article-node.ts +52 -0
  47. package/src/jats/importer/jats-comments.ts +111 -0
  48. package/src/jats/importer/jats-dom-parser.ts +1260 -0
  49. package/src/jats/importer/jats-parser-utils.ts +234 -0
  50. package/src/jats/importer/jats-transformations.ts +591 -0
  51. package/src/jats/importer/parse-jats-article.ts +106 -0
  52. package/src/jats/index.ts +21 -0
  53. package/src/jats/types.ts +16 -0
  54. package/src/lib/__tests__/footnotes.test.ts +36 -0
  55. package/src/lib/citeproc.ts +30 -0
  56. package/src/lib/credit-roles.ts +91 -0
  57. package/src/lib/deafults.ts +17 -0
  58. package/src/lib/footnotes.ts +85 -0
  59. package/src/lib/html.ts +56 -0
  60. package/src/lib/section-categories.ts +27 -0
  61. package/src/lib/utils.ts +145 -0
  62. package/src/lib/xml.ts +28 -0
  63. package/src/schema/__tests__/docs.ts +1911 -0
  64. package/src/schema/__tests__/groups.test.ts +61 -0
  65. package/src/schema/__tests__/migration.test.ts +23 -0
  66. package/src/schema/groups.ts +36 -0
  67. package/src/schema/index.ts +286 -0
  68. package/src/schema/marks.ts +254 -0
  69. package/src/schema/migration/migrate.ts +77 -0
  70. package/src/schema/migration/migration-script.ts +26 -0
  71. package/src/schema/migration/migration-scripts/1.2.5.ts +44 -0
  72. package/src/schema/migration/migration-scripts/2.3.22.ts +52 -0
  73. package/src/schema/migration/migration-scripts/3.0.12.ts +33 -0
  74. package/src/schema/migration/migration-scripts/3.0.21.ts +50 -0
  75. package/src/schema/migration/migration-scripts/3.0.30.ts +65 -0
  76. package/src/schema/migration/migration-scripts/3.0.31.ts +40 -0
  77. package/src/schema/migration/migration-scripts/3.0.41.ts +37 -0
  78. package/src/schema/migration/migration-scripts/3.0.55.ts +42 -0
  79. package/src/schema/migration/migration-scripts/3.0.56.ts +114 -0
  80. package/src/schema/migration/migration-scripts/4.2.13.ts +37 -0
  81. package/src/schema/migration/migration-scripts/4.2.15.ts +48 -0
  82. package/src/schema/migration/migration-scripts/4.3.23.ts +55 -0
  83. package/src/schema/migration/migration-scripts/4.3.34.ts +132 -0
  84. package/src/schema/migration/migration-scripts/4.3.35.ts +41 -0
  85. package/src/schema/migration/migration-scripts/index.ts +49 -0
  86. package/src/schema/nodes/abstracts.ts +29 -0
  87. package/src/schema/nodes/affiliation.ts +88 -0
  88. package/src/schema/nodes/affiliations.ts +30 -0
  89. package/src/schema/nodes/alt_text.ts +36 -0
  90. package/src/schema/nodes/alt_title.ts +40 -0
  91. package/src/schema/nodes/alt_titles_section.ts +58 -0
  92. package/src/schema/nodes/attachment.ts +46 -0
  93. package/src/schema/nodes/attachments.ts +45 -0
  94. package/src/schema/nodes/attribution.ts +38 -0
  95. package/src/schema/nodes/author_notes.ts +44 -0
  96. package/src/schema/nodes/award.ts +52 -0
  97. package/src/schema/nodes/awards.ts +45 -0
  98. package/src/schema/nodes/backmatter.ts +31 -0
  99. package/src/schema/nodes/bibliography_element.ts +58 -0
  100. package/src/schema/nodes/bibliography_item.ts +108 -0
  101. package/src/schema/nodes/bibliography_section.ts +60 -0
  102. package/src/schema/nodes/blockquote_element.ts +79 -0
  103. package/src/schema/nodes/body.ts +29 -0
  104. package/src/schema/nodes/box_element.ts +67 -0
  105. package/src/schema/nodes/caption.ts +67 -0
  106. package/src/schema/nodes/caption_title.ts +67 -0
  107. package/src/schema/nodes/citation.ts +70 -0
  108. package/src/schema/nodes/comment.ts +50 -0
  109. package/src/schema/nodes/comments.ts +28 -0
  110. package/src/schema/nodes/contributor.ts +87 -0
  111. package/src/schema/nodes/contributors.ts +40 -0
  112. package/src/schema/nodes/core_section.ts +27 -0
  113. package/src/schema/nodes/corresp.ts +49 -0
  114. package/src/schema/nodes/cross_reference.ts +64 -0
  115. package/src/schema/nodes/doc.ts +21 -0
  116. package/src/schema/nodes/embed.ts +55 -0
  117. package/src/schema/nodes/equation.ts +65 -0
  118. package/src/schema/nodes/equation_element.ts +61 -0
  119. package/src/schema/nodes/figure.ts +65 -0
  120. package/src/schema/nodes/figure_element.ts +73 -0
  121. package/src/schema/nodes/footnote.ts +95 -0
  122. package/src/schema/nodes/footnotes_element.ts +69 -0
  123. package/src/schema/nodes/footnotes_section.ts +61 -0
  124. package/src/schema/nodes/general_table_footnote.ts +42 -0
  125. package/src/schema/nodes/graphical_abstract_section.ts +62 -0
  126. package/src/schema/nodes/hard_break.ts +36 -0
  127. package/src/schema/nodes/hero_image.ts +46 -0
  128. package/src/schema/nodes/highlight_marker.ts +68 -0
  129. package/src/schema/nodes/image_element.ts +49 -0
  130. package/src/schema/nodes/inline_equation.ts +68 -0
  131. package/src/schema/nodes/inline_footnote.ts +66 -0
  132. package/src/schema/nodes/keyword.ts +61 -0
  133. package/src/schema/nodes/keyword_group.ts +63 -0
  134. package/src/schema/nodes/keywords.ts +59 -0
  135. package/src/schema/nodes/keywords_element.ts +64 -0
  136. package/src/schema/nodes/link.ts +79 -0
  137. package/src/schema/nodes/list.ts +134 -0
  138. package/src/schema/nodes/listing.ts +91 -0
  139. package/src/schema/nodes/listing_element.ts +61 -0
  140. package/src/schema/nodes/long_desc.ts +36 -0
  141. package/src/schema/nodes/manuscript.ts +86 -0
  142. package/src/schema/nodes/missing_figure.ts +59 -0
  143. package/src/schema/nodes/paragraph.ts +77 -0
  144. package/src/schema/nodes/placeholder.ts +62 -0
  145. package/src/schema/nodes/placeholder_element.ts +60 -0
  146. package/src/schema/nodes/pullquote_element.ts +81 -0
  147. package/src/schema/nodes/quote_image.ts +64 -0
  148. package/src/schema/nodes/section.ts +69 -0
  149. package/src/schema/nodes/section_label.ts +39 -0
  150. package/src/schema/nodes/section_title.ts +58 -0
  151. package/src/schema/nodes/subtitle.ts +40 -0
  152. package/src/schema/nodes/subtitles.ts +51 -0
  153. package/src/schema/nodes/supplement.ts +77 -0
  154. package/src/schema/nodes/supplements.ts +60 -0
  155. package/src/schema/nodes/table.ts +144 -0
  156. package/src/schema/nodes/table_col.ts +76 -0
  157. package/src/schema/nodes/table_element.ts +67 -0
  158. package/src/schema/nodes/table_element_footer.ts +42 -0
  159. package/src/schema/nodes/text.ts +31 -0
  160. package/src/schema/nodes/title.ts +43 -0
  161. package/src/schema/nodes/trans_abstract.ts +58 -0
  162. package/src/schema/nodes/trans_graphical_abstract.ts +67 -0
  163. package/src/schema/types.ts +240 -0
  164. package/src/tests.ts +33 -0
  165. package/src/transformer/id.ts +23 -0
  166. package/src/transformer/index.ts +21 -0
  167. package/src/transformer/node-names.ts +73 -0
  168. package/src/transformer/node-title.ts +111 -0
  169. package/src/transformer/node-types.ts +39 -0
  170. package/src/transformer/node-validator.ts +82 -0
  171. package/src/types.ts +25 -0
  172. package/src/version.ts +1 -0
@@ -0,0 +1,1561 @@
1
+ <?xml version="1.0" encoding="utf-8"?>
2
+ <article article-type="research-article" dtd-version="1.1" xml:lang="en"
3
+ xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
4
+ <front>
5
+ <journal-meta>
6
+ <journal-id journal-id-type="publisher-id">APA6</journal-id>
7
+ <journal-id journal-id-type="nlm-ta">Brain Behav</journal-id>
8
+ <journal-title-group>
9
+ <journal-title>Brain and Behavior</journal-title>
10
+ <abbrev-journal-title abbrev-type="pubmed">Brain Behav.</abbrev-journal-title>
11
+ </journal-title-group>
12
+ <issn pub-type="epub">2162-3279</issn>
13
+ <publisher>
14
+ <publisher-name>John Wiley and Sons</publisher-name>
15
+ </publisher>
16
+ </journal-meta>
17
+ <article-meta>
18
+ <article-id pub-id-type="doi">10.5555/BRB3-2019-12-0787</article-id>
19
+ <article-id pub-id-type="publisher-id">BRB3-2019-12-0787</article-id>
20
+ <article-categories>
21
+ <subj-group subj-group-type="heading">
22
+ <subject>Original Research</subject>
23
+ </subj-group>
24
+ </article-categories>
25
+ <title-group>
26
+ <article-title>Blood <bold>pressure</bold> after follow up in a stroke prevention
27
+ clinic</article-title>
28
+ <alt-title alt-title-type="running">Running title example</alt-title>
29
+ <alt-title alt-title-type="short">Short title example</alt-title>
30
+ </title-group>
31
+ <contrib-group>
32
+ <contrib contrib-type="author" corresp="yes">
33
+ <contrib-id contrib-id-type="orcid" authenticated="true"
34
+ >https://orcid.org/0000-0003-2217-5904</contrib-id>
35
+ <name>
36
+ <surname>Hornnes</surname>
37
+ <given-names>Agnete Hviid</given-names>
38
+ <suffix>Jr.</suffix>
39
+ </name>
40
+ <degrees>RN</degrees>
41
+ <degrees>MPH</degrees>
42
+ <degrees>PhD</degrees>
43
+ <role> author </role>
44
+ <prefix> Mr </prefix>
45
+ <xref ref-type="aff" rid="BRB3-2019-12-0787-aff1" />
46
+ <role vocab="CRediT"
47
+ vocab-identifier="http://credit.niso.org/"
48
+ vocab-term="Writing – original draft"
49
+ vocab-term-identifier=
50
+ "http://credit.niso.org/contributor-roles/writing-original-draft/"
51
+ degree-contribution="lead">writer</role>
52
+ </contrib>
53
+ <contrib contrib-type="author">
54
+ <name>
55
+ <surname>Poulsen</surname>
56
+ <given-names>Mai Bang</given-names>
57
+ </name>
58
+ <degrees>MD</degrees>
59
+ <degrees>PhD</degrees>
60
+ <xref ref-type="fn" rid="BRB3-2019-12-0787-afn-0001">*</xref>
61
+ <xref ref-type="aff" rid="BRB3-2019-12-0787-aff1" />
62
+ </contrib>
63
+ <aff id="BRB3-2019-12-0787-aff1"><institution content-type="dept">Department of
64
+ Neurology</institution>, <institution>Herlev og Gentofte
65
+ Hospital</institution>, <addr-line>Borgmester Ib Juuls Vej 1</addr-line>,
66
+ <addr-line><postal-code>2730</postal-code>
67
+ <city>Herlev</city></addr-line>, <country>Denmark</country></aff>
68
+ </contrib-group>
69
+ <author-notes>
70
+ <corresp id="BRB3-2019-12-0787-cor1">Corresponding author: Agnete Hviid
71
+ Hornnes&#x2028;<email xlink:href="agnete.hviid.hornnes@regionh.dk"
72
+ >agnete.hviid.hornnes@regionh.dk</email>&#x2028;FAX: 0045 3868
73
+ 4031</corresp>
74
+ <fn id="BRB3-2019-12-0787-afn-0001">
75
+ <label>*</label>
76
+ <p>Mai Bang Poulsen, MD, PhD&#x2028;Department of
77
+ Neurology&#x2028;Nordsj&#x00E6;llands Hospital&#x2028;Dyrehavevej
78
+ 29&#x2028;3400 Hiller&#x00F8;d&#x2028;Denmark</p>
79
+ </fn>
80
+ <fn id="BRB3-2019-12-0787-afn-0002">
81
+ <p>ClinicalTrials.gov NCT03782857.</p>
82
+ </fn>
83
+ <fn fn-type="con">
84
+ <p content-type="fn-title">Contributor Information</p>
85
+ <p>Agnete Hviid Hornnes, Email: agnete.hviid.hornnes@regionh.dk <ext-link
86
+ ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-2217-5904"
87
+ >https//orcid.org/0000-0003-2217-5904</ext-link>&#x2028;Mai Bang
88
+ Poulsen, Email: mai.bang.poulsen.02@regionh.dk</p>
89
+ <p>Both authors have made substantial contributions to conception and design and
90
+ acquisitions and
91
+ analyses
92
+ <?AuthorQuery id="Q3" queryText="Check meaning - US English uses different spellings for the noun &quot;analyses&quot; (more than one analysis) and the verb form &quot;analyzes&quot;"?>
93
+ and interpretation of data and have; and been involved in writing the
94
+ manuscript and given final approval of the version to be published. Both
95
+ authors have participated sufficiently in the work to take public
96
+ responsibility for the content; and agree to be accountable for all aspects
97
+ of the work in ensuring that questions related to the accuracy or integrity
98
+ of any part of the work are appropriately investigated and resolved.</p>
99
+ </fn>
100
+ </author-notes>
101
+ <pub-date pub-type="ppub">
102
+ <year />
103
+ </pub-date>
104
+ <volume />
105
+ <supplementary-material id="S1" xlink:href="attachment:7d9d686b-5488-44a5-a1c5-46351e7f9312" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document">
106
+ <caption>
107
+ <title>final manuscript-hum-huili-dbh-suicide-20200707_figures (9)
108
+ </title>
109
+ </caption>
110
+ <alt-text>example of alt text for supplements</alt-text>
111
+ <long-desc>example of long desc for supplements</long-desc>
112
+ </supplementary-material>
113
+ <history>
114
+ <date date-type="received">
115
+ <day>09</day>
116
+ <month>12</month>
117
+ <year>2019</year>
118
+ </date>
119
+ <date date-type="rev-recd">
120
+ <day />
121
+ <month />
122
+ <year />
123
+ </date>
124
+ <date date-type="accepted">
125
+ <day>27</day>
126
+ <month>04</month>
127
+ <year>2020</year>
128
+ </date>
129
+ </history>
130
+ <permissions> </permissions>
131
+ <self-uri content-type="document"
132
+ xlink:href="http://www.harmreductionjournal.com/content/1/1/5" />
133
+ <self-uri content-type="document"
134
+ xlink:href="http://www.harmreductionjournal.com/content/1/1/2" />
135
+
136
+ <abstract>
137
+ <sec>
138
+ <title>Objectives</title>
139
+ <p>In Denmark 25% of hospital admissions with stroke are recurrent strokes. With
140
+ thrombolytic treatment more patients survive with only minor disability.
141
+ This promising development should be followed up by intensive secondary
142
+ prevention. Hypertension is the most important target. We aimed at testing
143
+ the hypotheses that early follow up in a preventive clinic would result in
144
+ 1) A higher proportion of patients with blood pressure at target, 2) Time to
145
+ stroke recurrence, myocardial infarction and death would be longer in the
146
+ intervention group compared to controls.</p>
147
+ </sec>
148
+ <sec>
149
+ <title>Materials and Methods</title>
150
+ <p>Eligible patients admitted to the stroke unit of Herlev Hospital were
151
+ randomized shortly before discharge to intervention or control group. Of 78
152
+ included participants data from 73 was available for follow up nine months
153
+ after inclusion. Patients in the intervention group were seen in the clinic
154
+ within one week. In case of hypertension treatment was initiated or supplied
155
+ with a new drug. We used individual targets for blood pressure according to
156
+ diagnosis of stroke and patients&#x2019; comorbidity. Patients in the
157
+ intervention group had a median of five visits to the preventive clinic.</p>
158
+ </sec>
159
+ <sec>
160
+ <title>Results</title>
161
+ <p>In the intervention group blood pressure was treated to target in 25 patients
162
+ (69%) versus 14 (38%) in the control group
163
+ (<italic>p</italic>&#x2009;=&#x2009;0.007). Median time to first event was
164
+ 44 months (4&#x2013;49) in the intervention group and 19 months
165
+ (4&#x2013;37) in controls (<italic>p</italic>&#x2009;=&#x2009;0.316).</p>
166
+ </sec>
167
+ <sec>
168
+ <title>Conclusions</title>
169
+ <p>Treatment of hypertension to individual targets after stroke is feasible. It
170
+ may postpone recurrent stroke and death in stroke survivors.</p>
171
+ </sec>
172
+ </abstract>
173
+ <abstract abstract-type="graphical">
174
+ <fig id="fig-1" position="anchor" fig-type="half-left">
175
+ <graphic xlink:href="demo1.jpg" />
176
+ </fig>
177
+ </abstract>
178
+ <abstract abstract-type="key-image">
179
+ <fig id="fig-2" position="anchor" fig-type="half-left">
180
+ <graphic xlink:href="demo2.jpg" />
181
+ </fig>
182
+ </abstract>
183
+ <abstract abstract-type="short">
184
+ <p>The is the third and last part of the volume devoted to solubility data of rare
185
+ earth metal chlorides in water and in ternary and quaternary aqueous systems.
186
+ Compilations of all available experimental data are introduced for each rare earth
187
+ metal chloride with a corresponding critical evaluation. This part covers chlorides
188
+ of Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu, with coverage of the literature through the
189
+ middle of 2008.</p>
190
+ </abstract>
191
+ <trans-abstract abstract-type="short" xml:lang="fr">
192
+ <p>
193
+ Il s'agit de la troisième et dernière partie du volume consacrée aux données de solubilité
194
+ des chlorures de métaux des terres rares dans l'eau et dans les systèmes aqueux ternaires
195
+ et
196
+ quaternaires.
197
+ Une compilation de toutes les données expérimentales disponibles est présentée pour chaque
198
+ chlorure de métaux des terres rares, accompagnée de l'évaluation critique correspondante.
199
+ Cette partie couvre les chlorures de Gd, Tb, Dy, Ho, Er, Tm, Yb et Lu, avec une couverture
200
+ de la littérature jusqu'à mi-2008.
201
+ </p>
202
+ </trans-abstract>
203
+ <kwd-group kwd-group-type="author">
204
+ <title>KEYWORDS &#x2028;</title>
205
+ <kwd>secondary prevention</kwd>
206
+ <kwd>stroke recurrence</kwd>
207
+ <kwd>blood pressure</kwd>
208
+ <kwd>blood pressure target</kwd>
209
+ <kwd>randomized controlled trial</kwd>
210
+ </kwd-group>
211
+ <funding-group>
212
+ <award-group>
213
+ <funding-source>National Institutes of Health</funding-source>
214
+ <principal-award-recipient>Berkeley</principal-award-recipient>
215
+ <award-id>GM18458</award-id>
216
+ </award-group>
217
+ <award-group>
218
+ <funding-source>National Science Foundation</funding-source>
219
+ <award-id>DMS-0204674</award-id>
220
+ <award-id>DMS-0244638</award-id>
221
+ </award-group>
222
+ </funding-group>
223
+ <counts>
224
+ <count count-type="box" count="0"/>
225
+ <fig-count count="3"/>
226
+ <table-count count="2"/>
227
+ <equation-count count="0"/>
228
+ <ref-count count="25"/>
229
+ <word-count count="4484"/>
230
+ </counts>
231
+ </article-meta>
232
+ </front>
233
+ <body>
234
+ <graphic xlink:href="demo1.png">
235
+ <ext-link xlink:href="WLYSP_5_4_Infographic_Nov_11_2022.pdf"/>
236
+ <caption>
237
+ <title>Title...</title>
238
+ <p>simple image</p>
239
+ <p>caption</p>
240
+ </caption>
241
+ </graphic>
242
+ <graphic
243
+ xlink:href="prodbe.int.aip.org:8080/journal/journal_fs/
244
+ 1.2983775.1373315697!/images/1460725790.jpg">
245
+ <alt-text>example of alt text for graphics</alt-text>
246
+ <long-desc>example of long desc</long-desc>
247
+ </graphic>
248
+ <p>test paragraph</p>
249
+ <disp-quote content-type="quote-with-image">
250
+ <graphic content-type="headshot" xlink:href="demo1.jpg"/>
251
+ <p>It is a far, far better thing that I do now than I have ever done.</p>
252
+ <attrib>Charles Dickens</attrib>
253
+ </disp-quote>
254
+ <sec id="BRB3-2019-12-0787-sec1" sec-type="intro">
255
+ <label>1</label>
256
+ <title>INTRODUCTION</title>
257
+ <p>Over the last two decades continuous development of thrombolytic treatment of acute
258
+ ischemic stroke (IS) has improved safety and functional outcome in treated patients
259
+ <xref ref-type="bibr"
260
+ rid="BRB3-2019-12-0787-bib-0001 BRB3-2019-12-0787-bib-0002"
261
+ ><sup>1;2</sup></xref> thus increasing the possibility of survival with no or
262
+ only minor disability. With this fact and the ongoing aging of populations in mind
263
+ <xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0003"><sup>3</sup></xref> the
264
+ secondary prevention after stroke seems more important than ever. In 1998 the
265
+ Copenhagen Stroke Study reported a recurrence rate of 23%. <xref ref-type="bibr"
266
+ rid="BRB3-2019-12-0787-bib-0004"><sup>4</sup></xref> According to the Danish
267
+ Stroke Registry our national recurrence rate was 25% in 2011.<xref ref-type="bibr"
268
+ rid="BRB3-2019-12-0787-bib-0005"><sup>5</sup></xref></p>
269
+ <p>Hypertension is an important risk factor for stroke recurrence. <xref ref-type="bibr"
270
+ rid="BRB3-2019-12-0787-bib-0004 BRB3-2019-12-0787-bib-0006 BRB3-2019-12-0787-bib-0007 BRB3-2019-12-0787-bib-0008"
271
+ ><sup>4;6&#x2013;8</sup></xref> Lowering blood pressure (BP) after stroke or
272
+ transitory ischemic attack (TIA) by 10/5 mm Hg has been associated with reduced risk
273
+ of stroke recurrence by 24% and myocardial infarction (MI) by 21%. <xref
274
+ ref-type="bibr" rid="BRB3-2019-12-0787-bib-0009"><sup>9</sup></xref></p>
275
+ <p>Observational studies have demonstrated the difficulties in lowering BP after stroke
276
+ with rates of BP treated to target ranging from 28% to 73% <xref ref-type="bibr"
277
+ rid="BRB3-2019-12-0787-bib-0010 BRB3-2019-12-0787-bib-0011 BRB3-2019-12-0787-bib-0012 BRB3-2019-12-0787-bib-0013"
278
+ ><sup>10&#x2013;13</sup></xref> and interventions aimed at control of BP
279
+ after stroke have not yet found a successful model. <xref ref-type="bibr"
280
+ rid="BRB3-2019-12-0787-bib-0014 BRB3-2019-12-0787-bib-0015 BRB3-2019-12-0787-bib-0016 BRB3-2019-12-0787-bib-0017 BRB3-2019-12-0787-bib-0018 BRB3-2019-12-0787-bib-0019"
281
+ ><sup>14&#x2013;19</sup></xref> Fahey and coworkers have reviewed the
282
+ literature aimed at improving control of BP in hypertensive subjects. One large
283
+ study using an organized system of regular visits to a clinic was efficient in
284
+ producing a large decrease in BP and reduction of all-cause mortality compared to
285
+ referral to usual primary care. This was achieved by using a stepwise escalation of
286
+ treatment until target was reached. <xref ref-type="bibr"
287
+ rid="BRB3-2019-12-0787-bib-0020"><sup>20</sup></xref> Other methods had variable
288
+ or no effect, only nurse or pharmacist led care seemed promising.</p>
289
+ <media
290
+ xmlns:xlink="http://www.w3.org/1999/xlink"
291
+ xlink:href="example.mp4"
292
+ xlink:show="embed"
293
+ mimetype="video"
294
+ mime-subtype="mp4" >
295
+ <alt-text>example of alt text for media</alt-text>
296
+ <long-desc>example of long desc</long-desc>
297
+ </media>
298
+ <sec>
299
+ <title>Aims and hypotheses</title>
300
+ <p>The aim of the present study was to test the hypotheses that follow up after
301
+ stroke in a specialized nurse led physician supervised clinic with stepwise
302
+ escalation of BP- and lipid lowering treatment would result in</p>
303
+ <sec>
304
+ <title>Primary endpoint</title>
305
+ <sec>
306
+ <title>A greater proportion of participants with BP at target</title>
307
+ <p>Secondary endpoints:<list id="L1" list-type="simple">
308
+ <list-item>
309
+ <p>A greater reduction of BP</p>
310
+ </list-item>
311
+ <list-item>
312
+ <p>A greater proportion of participants with LDL-cholesterol
313
+ treated to target</p>
314
+ </list-item>
315
+ <list-item>
316
+ <p>A greater reduction of LDL-cholesterol</p>
317
+ </list-item>
318
+ <list-item>
319
+ <p>Longer time to recurrence of stroke, MI and death</p>
320
+ </list-item>
321
+ <list-item>
322
+ <p>in the intervention group compared to controls</p>
323
+ </list-item>
324
+ </list>
325
+ </p>
326
+ </sec>
327
+ </sec>
328
+ <sec>
329
+ <title>BoxedText test</title>
330
+ <boxed-text></boxed-text>
331
+ <boxed-text>
332
+ <label>BoxedTextLabel</label>
333
+ <caption>
334
+ <title>BoxedTextCaptionTitle</title>
335
+ </caption>
336
+ <sec>
337
+ <title>Key messages</title>
338
+ <list list-type="bullet">
339
+ <list-item>
340
+ <p>The benefits of geriatric day hospital care have been
341
+ controversial for many years.</p>
342
+ </list-item>
343
+ <list-item>
344
+ <p>This systematic review of 12 randomised trials comparing
345
+ a variety of day hospitals with a range of alternative
346
+ services found no overall advantage for day hospital care.</p>
347
+ </list-item>
348
+ <list-item>
349
+ <p>Day hospitals had a possible advantage over no comprehensive
350
+ care in terms of death or poor outcome, disability, and use of
351
+ resources.</p>
352
+ </list-item>
353
+ <list-item>
354
+ <p>The costs of day hospital care may be partly offset by
355
+ a reduced use of hospital beds and institutional care among
356
+ survivors.</p>
357
+ </list-item>
358
+ </list>
359
+ </sec>
360
+ <sec>
361
+ <title>testing multiple sections inside a boxed-text element</title>
362
+ <p>Hello World!</p>
363
+ </sec>
364
+ </boxed-text>
365
+ <boxed-text>
366
+ <label>BoxedTextLabel</label>
367
+
368
+ <sec>
369
+ <title>Key messages</title>
370
+ <list list-type="bullet">
371
+ <list-item>
372
+ <p>The benefits of geriatric day hospital care have been
373
+ controversial for many years.</p>
374
+ </list-item>
375
+ <list-item>
376
+ <p>This systematic review of 12 randomised trials comparing
377
+ a variety of day hospitals with a range of alternative
378
+ services found no overall advantage for day hospital care.</p>
379
+ </list-item>
380
+ <list-item>
381
+ <p>Day hospitals had a possible advantage over no comprehensive
382
+ care in terms of death or poor outcome, disability, and use of
383
+ resources.</p>
384
+ </list-item>
385
+ <list-item>
386
+ <p>The costs of day hospital care may be partly offset by
387
+ a reduced use of hospital beds and institutional care among
388
+ survivors.</p>
389
+ </list-item>
390
+ </list>
391
+ </sec>
392
+ </boxed-text>
393
+ </sec>
394
+ </sec>
395
+ </sec>
396
+ <sec id="BRB3-2019-12-0787-sec2" sec-type="methods">
397
+ <label>2</label>
398
+ <title>MATERIELS AND METHODS</title>
399
+ <p>Before the initiation of the study the authors attended a three-day course in
400
+ treatment of hypertension arranged by the Danish Society of Hypertension. The
401
+ recommendations of our national guidelines regarding BP targets were in line with
402
+ those given by the American Stroke Association in force at the time of initiation of
403
+ the study: &#x201C;An absolute target BP level and reduction are uncertain and
404
+ should be individualized.&#x201D; <xref ref-type="bibr"
405
+ rid="BRB3-2019-12-0787-bib-0021"><sup>21</sup></xref> Following the advice given
406
+ by the Danish Society of Hypertension we used the following targets: A BP
407
+ &lt;&#x2009;140/90 mm Hg was considered at target in non-diabetic patients. In
408
+ patients aged 80 years or more a BP of 150/90 mm Hg was acceptable if further
409
+ treatment was not tolerated. In case of severe carotid stenosis or a history of
410
+ ischemic heart disease BP should not be lower than 130/80 mm Hg. In patients with
411
+ diabetes or hemorrhagic stroke we aimed at a BP&#x2009;&lt;&#x2009;130/80 mm Hg.
412
+ Untreated patients without hypertension were categorized as normotensive, untreated
413
+ hypertensive patients as having unknown hypertension, treated patients without
414
+ hypertension as treated to target, and treated patients with hypertension as having
415
+ untreated hypertension.</p>
416
+ <p>LDL-cholesterol should be &lt;&#x2009;2.5 mmol/l in patients with IS or TIA in
417
+ non-diabetic patients and in case of diabetes &lt;&#x2009;2.0 mmol/l.</p>
418
+ <p>A sample size calculation showed that 24 patients in each group were needed to show a
419
+ difference of 10 mm Hg in the development of systolic BP (80% power).</p>
420
+ <sec id="BRB3-2019-12-0787-sec2.1">
421
+ <label>2.1</label>
422
+ <title>Study sample and setting</title>
423
+ <p>From June 2012 to February 2013 all patients diagnosed with a stroke or TIA at
424
+ the stroke unit of Herlev Gentofte Hospital, University of Copenhagen were
425
+ considered for inclusion in the study. Patients should be without cognitive
426
+ deficits that would prevent their active participation and they should be
427
+ discharged to their own home. The last author used computer-generated block
428
+ randomization procedures with stratification by hypertension (1:1). The
429
+ allocation sequence was concealed, and we aimed at equal numbers in the two
430
+ groups. Shortly before discharge the first author approached eligible patients
431
+ for oral and written information about the study. Where written informed consent
432
+ to participation was achieved BP was measured before a concealed envelope
433
+ administered by a secretary was opened revealing the allocation to either
434
+ intervention or control group.</p>
435
+ <p>The research protocol was approved by the ethics committee of the Capital Region
436
+ of Denmark (H-3-2011&#x2013;152) and by the Danish Data Protection Agency
437
+ (2012&#x2013;41-0429). The study was conducted according to all common ethical
438
+ standards including the rules given by the Declaration of Helsinki. Patients
439
+ randomized to the control group had the usual treatment: one visit in the
440
+ outpatient clinic of the stroke unit three months after discharge. Patients
441
+ randomized to the intervention group had an appointment with the first author
442
+ within one week after discharge. The first author undertook all visits in the
443
+ preventive clinic.</p>
444
+ </sec>
445
+ <sec id="BRB3-2019-12-0787-sec2.2">
446
+ <label>2.2</label>
447
+ <title>Procedures and intervention</title>
448
+ <p>BP was measured at every visit after at least five minutes rest in a sitting
449
+ position in an arm chair. BP was measured simultaneously in both arms followed
450
+ by two measurements with 10-min intervals using the arm with the highest
451
+ systolic BP. In case of hypertension the first author would suggest initiation
452
+ or intensification of antihypertensive treatment. The last author would accept
453
+ or suggest an alternative and do the prescription. Patients would come to the
454
+ clinic for control of BP and relevant blood tests every 3&#x2013;4 weeks until
455
+ BP was at target. After five weeks on lipid lowering drugs treatment was
456
+ intensified if needed. Patients who did not tolerate lipid lowering medication
457
+ were referred to a dietitian. In motivated patients home BP measurements were
458
+ performed using patients&#x2019; own monitor or by lending patients a BP monitor
459
+ between visits.</p>
460
+ <p>Patients in the intervention group had a mean of five visits to the clinic with
461
+ addition of new drugs rather than adding more of the same drug in case of
462
+ hypertension. Although we used minimum doses to prevent adverse effects, many
463
+ patients had unacceptable side effects necessitating change to another class of
464
+ antihypertensive drug.</p>
465
+ <p>Patients were informed about the importance of life-long adherence with all
466
+ preventive medication. Those with elevated BP or receiving antihypertensive
467
+ treatment were advised in salt reduction, smokers were advised to stop smoking
468
+ and all patients were informed about the benefits of 30 min of moderate physical
469
+ activity daily. Likewise, information about the risk of an intake of alcohol
470
+ above seven drinks per week in women and 14 drinks in men was part of the
471
+ program as well as the benefits of weight reduction in overweight patients with
472
+ hypertension or diabetes.</p>
473
+ </sec>
474
+ <sec id="BRB3-2019-12-0787-sec2.3">
475
+ <label>2.3</label>
476
+ <title>Follow up</title>
477
+ <p>Participants in both groups were invited to the usual follow up visit three
478
+ months after discharge at the outpatient clinic of the stroke unit as well as a
479
+ follow up visit in the study a median of 9 (IQR 8&#x2013;11) months after
480
+ inclusion.</p>
481
+ <p>In accordance with the protocol the final follow up visits were performed by
482
+ nurses in the outpatient clinic with measurement of BP and blood-cholesterols.
483
+ Patients were asked not to reveal their group allocation but blinding of the
484
+ nurses was not possible. Patients were interviewed about adherence to all
485
+ preventive medications as well as their present life style. For practical
486
+ purposes a minority of visits were performed by the first author. To do
487
+ intention to treat
488
+ analyses<?AuthorQuery id="Q1" queryText="Check meaning - US English uses different spellings for the noun &quot;analyses&quot; (more than one analysis) and the verb form &quot;analyzes&quot;"?>
489
+ we used last observation carried forward regarding the endpoints of the study
490
+ where patients had died or did not respond to the invitation to a follow up
491
+ visit. Thus, we used the last recorded values in five patients in the
492
+ intervention group and in seven controls.</p>
493
+ <p>After a median of 65 months (IQR: 61&#x2013;66) from inclusion data on vascular
494
+ events and death were attained from the hospital based medical records covering
495
+ all hospitals of the region.</p>
496
+ </sec>
497
+ <sec id="BRB3-2019-12-0787-sec2.4">
498
+ <label>2.4</label>
499
+ <title>Statistics</title>
500
+ <p>Data were entered into Excel and imported into SAS. Statistical
501
+ analyses<?AuthorQuery id="Q2" queryText="Check meaning - US English uses different spellings for the noun &quot;analyses&quot; (more than one analysis) and the verb form &quot;analyzes&quot;"?>
502
+ were performed by the first author according to a pre-established statistical
503
+ analysis plan. We used Chi square test (for the primary outcome) or
504
+ Fisher&#x2019;s exact test as appropriate for comparison of proportions, and for
505
+ change from baseline we used McNemar&#x2019;s test. For continuous variables we
506
+ used t-test or Mann-Whitney&#x2019;s test*. Change from baseline was analyzed by
507
+ the paired t-test or Wilcoxon signed rank sum test* (*where data were not
508
+ normally distributed). We used SAS 9.4 for Windows and
509
+ <italic>p</italic>&#x2009;&lt;&#x2009;0.05 was considered significant.</p>
510
+ </sec>
511
+ </sec>
512
+ <sec id="BRB3-2019-12-0787-sec3" sec-type="results">
513
+ <label>3</label>
514
+ <title>RESULTS</title>
515
+ <p>We included 78 patients in the study. Due to revision of stroke diagnoses in four
516
+ participants and as one participant never turned up for the intervention, data on 73
517
+ participants were available for follow up (<xref ref-type="fig"
518
+ rid="BRB3-2019-12-0787-fig-0001">Figure 1</xref>). The median stay in hospital
519
+ was 4 days (IQR: 3&#x2013;6). As seen from <xref ref-type="table"
520
+ rid="BRB3-2019-12-0787-tbl-0001">Table 1</xref> most participants had no or
521
+ slight disability.</p>
522
+ <fig id="BRB3-2019-12-0787-fig-0001" position="float" fig-type="half-left">
523
+ <label>FIGURE 1</label>
524
+ <caption>
525
+ <p>Flow chart of participants</p>
526
+ </caption>
527
+ <alt-text>example of alt text for figs</alt-text>
528
+ <long-desc>example of long desc</long-desc>
529
+ <graphic xlink:href="BRB3-2019-12-0787-fig-0001.png">
530
+ <alt-text>example of alt text for graphics inside figures</alt-text>
531
+ <long-desc>example of long desc for graphics inside figures</long-desc>
532
+ </graphic>
533
+ </fig>
534
+ <table-wrap id="BRB3-2019-12-0787-tbl-0001" position="float">
535
+ <label>TABLE 1</label>
536
+ <caption>
537
+ <title>Baseline characteristics of 73 patients</title>
538
+ </caption>
539
+ <alt-text>example of alt text for tables</alt-text>
540
+ <long-desc>example of long desc</long-desc>
541
+ <table frame="hsides" rules="groups">
542
+ <col width="52.14%"/>
543
+ <col width="11.92%"/>
544
+ <col width="14.9%"/>
545
+ <col width="13.1%"/>
546
+ <col width="7.94%"/>
547
+ <thead>
548
+ <tr>
549
+ <th valign="top" align="left" scope="col"
550
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
551
+ >Characteristics</th>
552
+ <th valign="top" align="left" scope="col"
553
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
554
+ >All<break/>(<italic>n</italic>&#x2009;=&#x2009;73)</th>
555
+ <th valign="top" align="left" scope="col"
556
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
557
+ >Intervention (<italic>n</italic>&#x2009;=&#x2009;36)</th>
558
+ <th valign="top" align="left" scope="col"
559
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
560
+ >Control (<italic>n</italic>&#x2009;=&#x2009;37)</th>
561
+ <th valign="top" align="left" scope="col"
562
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt">P</th>
563
+ </tr>
564
+ </thead>
565
+ <tbody>
566
+ <tr>
567
+ <td valign="middle" align="left" style="border-top: solid 0.50pt"
568
+ scope="row">Sex, female</td>
569
+ <td valign="middle" align="left" style="border-top: solid 0.50pt">29
570
+ (40)</td>
571
+ <td valign="middle" align="left" style="border-top: solid 0.50pt">15
572
+ (42)</td>
573
+ <td valign="middle" align="left" style="border-top: solid 0.50pt">14
574
+ (38)</td>
575
+ <td valign="middle" align="left" style="border-top: solid 0.50pt"
576
+ >0.74</td>
577
+ </tr>
578
+ <tr>
579
+ <td valign="middle" align="left" scope="row">Age (years),
580
+ mean&#x2009;&#x00B1;&#x2009;SD</td>
581
+ <td valign="middle" align="left">66&#x2009;&#x00B1;&#x2009;12</td>
582
+ <td valign="middle" align="left">63&#x2009;&#x00B1;&#x2009;13</td>
583
+ <td valign="middle" align="left">68&#x2009;&#x00B1;&#x2009;11</td>
584
+ <td valign="middle" align="left">0.08</td>
585
+ </tr>
586
+ <tr>
587
+ <td valign="top" align="left" scope="row">Length of
588
+ education<break/>&lt;&#x2009;10 years<break/>10 &#x2013; 12
589
+ years<break/>&gt;&#x2009;12 years</td>
590
+ <td valign="top" align="left">12 (17)<break/>22 (30)<break/>38 (53)</td>
591
+ <td valign="top" align="left">6 (17)<break/>10 (29)<break/>19 (54)</td>
592
+ <td valign="top" align="left">6 (16)<break/>12 (33)<break/>19 (51)</td>
593
+ <td valign="top" align="left">0.95</td>
594
+ </tr>
595
+ <tr>
596
+ <td valign="top" align="left" scope="row">Diagnosis of
597
+ stroke<break/>Ischemic Stroke<break/>TIA<break/>Hemorrhagic
598
+ stroke</td>
599
+ <td valign="top" align="left">63 (87)<break/>9 (12)<break/>1 (1)</td>
600
+ <td valign="top" align="left">33 (92)<break/>3 (8)</td>
601
+ <td valign="top" align="left">30 (81)<break/>6 (16)<break/>1 (3)</td>
602
+ <td valign="top" align="left">0.60<sup>a</sup></td>
603
+ </tr>
604
+ <tr>
605
+ <td valign="top" align="left" scope="row">Recurrent stroke</td>
606
+ <td valign="top" align="left">11 (15)</td>
607
+ <td valign="top" align="left">5 (14)</td>
608
+ <td valign="top" align="left">6 (16)</td>
609
+ <td valign="top" align="left">1.00<sup>a</sup></td>
610
+ </tr>
611
+ <tr>
612
+ <td valign="top" align="left" scope="row">Modified Rankin Scale score
613
+ &gt;&#x2009;2</td>
614
+ <td valign="top" align="left">5 (6)</td>
615
+ <td valign="top" align="left">1 (3)</td>
616
+ <td valign="top" align="left">4 (11)</td>
617
+ <td valign="top" align="left">0.36<sup>a</sup></td>
618
+ </tr>
619
+ <tr>
620
+ <td valign="top" align="left" scope="row">Antihypertensive medication
621
+ before stroke</td>
622
+ <td valign="top" align="left">39 (53)</td>
623
+ <td valign="top" align="left">15 (42)</td>
624
+ <td valign="top" align="left">24 (65)</td>
625
+ <td valign="top" align="left">0.047</td>
626
+ </tr>
627
+ <tr>
628
+ <td valign="top" align="left" scope="row">Antihypertensive medication at
629
+ discharge</td>
630
+ <td valign="top" align="left">46 (63)</td>
631
+ <td valign="top" align="left">20 (56)</td>
632
+ <td valign="top" align="left">26 (70)</td>
633
+ <td valign="top" align="left">0.19</td>
634
+ </tr>
635
+ <tr>
636
+ <td valign="top" align="left" scope="row">Cholesterol lowering
637
+ medication before stroke</td>
638
+ <td valign="top" align="left">25 (34)</td>
639
+ <td valign="top" align="left">11 (31)</td>
640
+ <td valign="top" align="left">14 (38)</td>
641
+ <td valign="top" align="left">0.51</td>
642
+ </tr>
643
+ <tr>
644
+ <td valign="top" align="left" scope="row">Cholesterol lowering
645
+ medication at discharge</td>
646
+ <td valign="top" align="left">65 (89)</td>
647
+ <td valign="top" align="left">35 (97)</td>
648
+ <td valign="top" align="left">30 (81)</td>
649
+ <td valign="top" align="left">0.03</td>
650
+ </tr>
651
+ <tr>
652
+ <td valign="top" align="left" scope="row">Diabetes at baseline</td>
653
+ <td valign="top" align="left">14 (19)</td>
654
+ <td valign="top" align="left">5 (14)</td>
655
+ <td valign="top" align="left">9 (24)</td>
656
+ <td valign="top" align="left">0.37<sup>a</sup></td>
657
+ </tr>
658
+ <tr>
659
+ <td valign="top" align="left" scope="row">Diabetes at discharge</td>
660
+ <td valign="top" align="left">16 (22)</td>
661
+ <td valign="top" align="left">6 (17)</td>
662
+ <td valign="top" align="left">10 (27)</td>
663
+ <td valign="top" align="left">0.29</td>
664
+ </tr>
665
+ <tr>
666
+ <td valign="top" align="left" scope="row">Atrial fibrillation at
667
+ baseline</td>
668
+ <td valign="top" align="left">7 (10)</td>
669
+ <td valign="top" align="left">3 (8)</td>
670
+ <td valign="top" align="left">4 (11)</td>
671
+ <td valign="top" align="left">1.00<sup>a</sup></td>
672
+ </tr>
673
+ <tr>
674
+ <td valign="top" align="left" scope="row">Atrial fibrillation at
675
+ discharge</td>
676
+ <td valign="top" align="left">12 (16)</td>
677
+ <td valign="top" align="left">6 (16)</td>
678
+ <td valign="top" align="left">6 (17)</td>
679
+ <td valign="top" align="left">1.00</td>
680
+ </tr>
681
+ <tr>
682
+ <td valign="top" align="left" scope="row">Unhealthy
683
+ dieting<sup>b</sup></td>
684
+ <td valign="top" align="left">59 (82)</td>
685
+ <td valign="top" align="left">25 (71)</td>
686
+ <td valign="top" align="left">34 (92)</td>
687
+ <td valign="top" align="left">0.03</td>
688
+ </tr>
689
+ <tr>
690
+ <td valign="top" align="left" scope="row">Current smoking</td>
691
+ <td valign="top" align="left">19 (26)</td>
692
+ <td valign="top" align="left">11 (31)</td>
693
+ <td valign="top" align="left">8 (22)</td>
694
+ <td valign="top" align="left">0.62</td>
695
+ </tr>
696
+ <tr>
697
+ <td valign="top" align="left" scope="row">Alcohol above
698
+ limits<sup>c</sup></td>
699
+ <td valign="top" align="left">23 (32)</td>
700
+ <td valign="top" align="left">12 (34)</td>
701
+ <td valign="top" align="left">11 (30)</td>
702
+ <td valign="top" align="left">0.68</td>
703
+ </tr>
704
+ <tr>
705
+ <td valign="top" align="left" scope="row">Sedentary
706
+ lifestyle<sup>d</sup></td>
707
+ <td valign="top" align="left">17 (24)</td>
708
+ <td valign="top" align="left">9 (26)</td>
709
+ <td valign="top" align="left">8 (22)</td>
710
+ <td valign="top" align="left">0.68</td>
711
+ </tr>
712
+ <tr>
713
+ <td valign="top" align="left" scope="row"
714
+ >BMI&#x2009;&#x2265;&#x2009;25</td>
715
+ <td valign="top" align="left">46 (63)</td>
716
+ <td valign="top" align="left">24 (67)</td>
717
+ <td valign="top" align="left">22 (59)</td>
718
+ <td valign="top" align="left">0.52</td>
719
+ </tr>
720
+ <tr>
721
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
722
+ scope="row">Self-rated health: fair, poor, or very poor</td>
723
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">34
724
+ (47)</td>
725
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">15
726
+ (43)</td>
727
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">19
728
+ (51)</td>
729
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
730
+ >0.47</td>
731
+ </tr>
732
+ </tbody>
733
+ </table>
734
+ <table-wrap-foot>
735
+ <p>Values are expressed as frequencies (%) or as
736
+ mean&#x2009;&#x00B1;&#x2009;standard deviations</p>
737
+ <fn id="BRB3-2019-12-0787-tfn1">
738
+ <label><sup>a</sup></label>
739
+ <p>Fisher&#x2019;s exact test. <sup>b</sup> Less than 600 g of fruit and
740
+ vegetables per day, fish for dinner less than twice per week.
741
+ <sup>c</sup> More than 7 drinks per week in women/more than 14
742
+ drinks per week in men. <sup>d</sup> Less than 30 min of moderate
743
+ physical activity per day.</p>
744
+ </fn>
745
+ </table-wrap-foot>
746
+ </table-wrap>
747
+ <p>Less than 20% of patients had a baseline BP treated to target (<xref ref-type="fig"
748
+ rid="BRB3-2019-12-0787-fig-0002">Figure 2</xref>). Twenty-eight patients (78%)
749
+ in the intervention group and 29 patients (78%) in the control group had a 3-month
750
+ visit in the outpatient clinic. Here 15 patients (42%) in the intervention group had
751
+ their BP and blood cholesterol measured and so had 23 patients (62%) in the control
752
+ group. At follow up patients in both groups reported a median of two visits
753
+ including BP measurement at the general practitioner&#x00B4;s office since discharge
754
+ from hospital.</p>
755
+ <fig id="BRB3-2019-12-0787-fig-0002" position="float" fig-type="half-left">
756
+ <label>FIGURE 2</label>
757
+ <caption>
758
+ <p>Blood pressure and treatment of hypertension at baseline in 73 patients
759
+ (%)</p>
760
+ </caption>
761
+ <graphic xlink:href="BRB3-2019-12-0787-fig-0002.png"/>
762
+ </fig>
763
+ <sec id="BRB3-2019-12-0787-sec3.1">
764
+ <label>3.1</label>
765
+ <title>Primary endpoint</title>
766
+ <p>Follow up visits showed that 25 patients (69%) in the intervention group had a BP
767
+ at target versus 14 (38%) of controls
768
+ (<italic>p</italic>&#x2009;=&#x2009;0.007). In four patients (10%) in the
769
+ intervention group antihypertensive medication remained unchanged since
770
+ discharge versus 23 (62%) of controls
771
+ (<italic>p</italic>&#x2009;&lt;&#x2009;0.0001) illustrated by the differences in
772
+ BP treated to target as well as untreated hypertension in <xref ref-type="fig"
773
+ rid="BRB3-2019-12-0787-fig-0003">Figure 3</xref>.</p>
774
+ <fig id="BRB3-2019-12-0787-fig-0003" position="float" fig-type="half-left">
775
+ <label>FIGURE 3</label>
776
+ <caption>
777
+ <p>Blood pressure and treatment of hypertension at follow up in 73 patients
778
+ (%)</p>
779
+ </caption>
780
+ <graphic xlink:href="BRB3-2019-12-0787-fig-0003.png"/>
781
+ </fig>
782
+ </sec>
783
+ <sec id="BRB3-2019-12-0787-sec3.2">
784
+ <label>3.2</label>
785
+ <title>Secondary endpoints</title>
786
+ <p>Median reduction in systolic BP was 11 mm Hg (-5-19) with 14 mm Hg (IQR:
787
+ 5&#x2013;21) in the intervention group and 3 mm Hg (IQR -11-17) in the control
788
+ group (<italic>p</italic>&#x2009;=&#x2009;0.045). Median reduction in diastolic
789
+ BP was 2 mm Hg (-2-11) with 7 mm Hg (IQR -1-13) in the intervention group and 1
790
+ mm Hg (IQR -6-8) in the control group
791
+ (<italic>p</italic>&#x2009;=&#x2009;0.04).</p>
792
+ <p>There was no difference between the groups regarding LDL-cholesterol treated to
793
+ target with 32 patients (89%) at target in the intervention group versus 29
794
+ patients (78%) in the control group (<italic>p</italic>&#x2009;=&#x2009;0.21).
795
+ We found significant reductions in LDL-cholesterol in both groups, but no
796
+ difference between the groups: 1.6 (IQR: 0.4&#x2013;2.2) mmol/l in the
797
+ intervention group versus 0.8 (IQR: 0.4&#x2013;1.8) mmol/l among controls
798
+ (<italic>p</italic>&#x2009;=&#x2009;0.18).</p>
799
+ <p>In 11 patients (31%) in the intervention group cholesterol lowering medication
800
+ remained unchanged since discharge versus 29 (78%) of controls
801
+ (<italic>p</italic>&#x2009;&lt;&#x2009;0.0001).</p>
802
+ <p>The combined endpoint of both BP and LDL-cholesterol at target was achieved in 22
803
+ (61%) of patients in the intervention group and in 10 patients (27%) in the
804
+ control group (<italic>p</italic>&#x2009;=&#x2009;0.003). At the end of the
805
+ study 24 patients (68%) in the intervention group measured their BP at home
806
+ versus 14 (38%) of controls (<italic>p</italic>&#x2009;=&#x2009;0.03).</p>
807
+ <p>The only significant change in lifestyle was a reduction in current smokers by
808
+ four in the control group (<xref ref-type="table"
809
+ rid="BRB3-2019-12-0787-tbl-0002">Table 2</xref>).</p>
810
+ <table-wrap id="BRB3-2019-12-0787-tbl-0002" position="float">
811
+ <label>TABLE 2</label>
812
+ <caption>
813
+ <title>Nine months follow up of 73 patients</title>
814
+ </caption>
815
+ <table frame="hsides" rules="groups">
816
+ <col width="52.91%"/>
817
+ <col width="11.06%"/>
818
+ <col width="14.16%"/>
819
+ <col width="11.5%"/>
820
+ <col width="10.37%"/>
821
+ <thead>
822
+ <tr>
823
+ <th valign="top" align="left" scope="col"
824
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
825
+ >Characteristics</th>
826
+ <th valign="top" align="left" scope="col"
827
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
828
+ >All<break/>(<italic>n</italic>&#x2009;=&#x2009;73)</th>
829
+ <th valign="top" align="left" scope="col"
830
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
831
+ >Intervention<break/>(<italic>n</italic>&#x2009;=&#x2009;36)</th>
832
+ <th valign="top" align="left" scope="col"
833
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
834
+ >Control<break/>(<italic>n</italic>&#x2009;=&#x2009;37)</th>
835
+ <th valign="top" align="left" scope="col"
836
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
837
+ >P</th>
838
+ </tr>
839
+ </thead>
840
+ <tbody>
841
+ <tr>
842
+ <td valign="top" align="left" style="border-top: solid 0.50pt"
843
+ scope="row">Systolic BP, mm Hg, mean &#x00B1;&#x2009;SD</td>
844
+ <td valign="top" align="left" style="border-top: solid 0.50pt">134
845
+ &#x00B1;&#x2009;21</td>
846
+ <td valign="top" align="left" style="border-top: solid 0.50pt">130
847
+ &#x00B1;&#x2009;17</td>
848
+ <td valign="top" align="left" style="border-top: solid 0.50pt">137
849
+ &#x00B1;&#x2009;24</td>
850
+ <td valign="top" align="left" style="border-top: solid 0.50pt"
851
+ >0.12</td>
852
+ </tr>
853
+ <tr>
854
+ <td valign="top" align="left" scope="row">Diastolic BP, mm Hg, mean
855
+ &#x00B1;&#x2009;SD</td>
856
+ <td valign="top" align="left">78 &#x00B1;&#x2009;11</td>
857
+ <td valign="top" align="left">78 &#x00B1;&#x2009;10</td>
858
+ <td valign="top" align="left">78 &#x00B1;&#x2009;12.8)</td>
859
+ <td valign="top" align="left">0.94</td>
860
+ </tr>
861
+ <tr>
862
+ <td valign="top" align="left" scope="row">Antihypertensive
863
+ medication</td>
864
+ <td valign="top" align="left">55 (75)</td>
865
+ <td valign="top" align="left">29 (81)</td>
866
+ <td valign="top" align="left">26 (70)</td>
867
+ <td valign="top" align="left">0.31</td>
868
+ </tr>
869
+ <tr>
870
+ <td valign="top" align="left" scope="row">100% compliance with AHM
871
+ (<italic>n</italic>&#x2009;=&#x2009;45)</td>
872
+ <td valign="top" align="left">38 (84)</td>
873
+ <td valign="top" align="left">23 (89)</td>
874
+ <td valign="top" align="left">15 (79)</td>
875
+ <td valign="top" align="left">0.38</td>
876
+ </tr>
877
+ <tr>
878
+ <td valign="top" align="left" scope="row">LDL-cholesterol, mmol/l
879
+ (<italic>n</italic>&#x2009;=&#x2009;72), mean
880
+ &#x00B1;&#x2009;SD</td>
881
+ <td valign="top" align="left">1.9 &#x00B1;&#x2009;0.8</td>
882
+ <td valign="top" align="left">1.9 &#x00B1;&#x2009;0.7</td>
883
+ <td valign="top" align="left">2.0 &#x00B1;&#x2009;0.8</td>
884
+ <td valign="top" align="left">0.66</td>
885
+ </tr>
886
+ <tr>
887
+ <td valign="top" align="left" scope="row">Cholesterol lowering
888
+ medication</td>
889
+ <td valign="top" align="left">64 (88)</td>
890
+ <td valign="top" align="left">32 (89)</td>
891
+ <td valign="top" align="left">32 (86)</td>
892
+ <td valign="top" align="left">0.76</td>
893
+ </tr>
894
+ <tr>
895
+ <td valign="top" align="left" scope="row">100% compliance with CLM
896
+ (<italic>n</italic>&#x2009;=&#x2009;52)</td>
897
+ <td valign="top" align="left">46 (89)</td>
898
+ <td valign="top" align="left">24 (86)</td>
899
+ <td valign="top" align="left">22 (92)</td>
900
+ <td valign="top" align="left">0.50</td>
901
+ </tr>
902
+ <tr>
903
+ <td valign="top" align="left" scope="row">Unhealthy
904
+ dieting<sup>b</sup></td>
905
+ <td valign="top" align="left">59 (81)</td>
906
+ <td valign="top" align="left">26 (72)</td>
907
+ <td valign="top" align="left">33 (89)</td>
908
+ <td valign="top" align="left">0.76</td>
909
+ </tr>
910
+ <tr>
911
+ <td valign="top" align="left" scope="row">Current smoker</td>
912
+ <td valign="top" align="left">15 (21)</td>
913
+ <td valign="top" align="left">11 (31)</td>
914
+ <td valign="top" align="left">4 (11)</td>
915
+ <td valign="top" align="left">0.046<sup>a</sup></td>
916
+ </tr>
917
+ <tr>
918
+ <td valign="top" align="left" scope="row"
919
+ >Alcohol&#x2009;&gt;&#x2009;limits<sup>c</sup></td>
920
+ <td valign="top" align="left">20 (27)</td>
921
+ <td valign="top" align="left">11 (31)</td>
922
+ <td valign="top" align="left">9 (24)</td>
923
+ <td valign="top" align="left">0.55</td>
924
+ </tr>
925
+ <tr>
926
+ <td valign="top" align="left" scope="row">Sedentary
927
+ lifestyle<sup>d</sup></td>
928
+ <td valign="top" align="left">16 (22)</td>
929
+ <td valign="top" align="left">7 (20)</td>
930
+ <td valign="top" align="left">9 (24)</td>
931
+ <td valign="top" align="left">0.66</td>
932
+ </tr>
933
+ <tr>
934
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
935
+ scope="row">BMI&#x2009;&#x2265;&#x2009;25</td>
936
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">43
937
+ (59)</td>
938
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">21
939
+ (58)</td>
940
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">22
941
+ (60)</td>
942
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
943
+ >0.92</td>
944
+ </tr>
945
+ </tbody>
946
+ </table>
947
+ <table-wrap-foot>
948
+ <p>Values are expressed as frequencies (%) or as
949
+ mean&#x2009;&#x00B1;&#x2009;standard deviations.&#x2028;Abbreviations:
950
+ AHM, antihypertensive medication; CLM, cholesterol lowering
951
+ medication.</p>
952
+ <fn id="BRB3-2019-12-0787-tfn2">
953
+ <label><sup>a</sup></label>
954
+ <p>Fisher&#x2019;s exact test. <sup>b</sup> Less than 600 g of fruit and
955
+ vegetables per day, fish for dinner less than twice per week.
956
+ <sup>c</sup> More than 7 drinks per week in women/more than 14
957
+ drinks per week in men. <sup>d</sup> Less than 30 min of moderate
958
+ physical activity per day.</p>
959
+ </fn>
960
+ <p/>
961
+ </table-wrap-foot>
962
+ </table-wrap>
963
+ <p>Regarding vascular complications and death, we found 32 events in 22 patients
964
+ after a median of 65 months. Median time to first event was 26 months (IQR:
965
+ 4&#x2013;49) with a median of 44 months (IQR: 11&#x2013;49) in the intervention
966
+ group and 19 months (IQR: 4&#x2013;37) in the control group
967
+ (<italic>p</italic>&#x2009;=&#x2009;0.32). All in all, we found 11 events in
968
+ nine patients in the intervention group: two recurrent strokes, three cases of
969
+ TIA, and six patients died versus 21 events in 13 patients in the control group:
970
+ seven recurrent strokes, five cases of TIA, one MI, and seven patients died
971
+ (<italic>p</italic>&#x2009;=&#x2009;0.49).</p>
972
+ </sec>
973
+ </sec>
974
+ <sec id="BRB3-2019-12-0787-sec4" sec-type="discussion">
975
+ <label>4</label>
976
+ <title>DISCUSSION</title>
977
+ <p>In this randomized clinical trial, a larger proportion of patients in the
978
+ intervention group compared to controls had BP within the above-mentioned limits and
979
+ the study fulfilled the aim of the primary endpoint.</p>
980
+ <p>A systematic review of interventions aimed at modifiable risk factor control for
981
+ secondary prevention of stroke revealed improvement in achieving BP target. <xref
982
+ ref-type="bibr" rid="BRB3-2019-12-0787-bib-0022"><sup>22</sup></xref> However,
983
+ as opposed to our study the review showed no significant change in systolic og
984
+ diastolic BP.</p>
985
+ <p>In a study of integrated care with five prearranged visits to patients&#x2019;
986
+ general practitioner versus usual care systolic BP at target set to 140 mm Hg was
987
+ found in 75% versus 58% at 12-month follow up. <xref ref-type="bibr"
988
+ rid="BRB3-2019-12-0787-bib-0019"><sup>19</sup></xref> We set individual targets
989
+ for BP according to patients&#x2019; type of stroke, comorbidities and age. This is
990
+ well in line with recommendations given by European Society of Hypertension, <xref
991
+ ref-type="bibr" rid="BRB3-2019-12-0787-bib-0023"><sup>23</sup></xref> but as
992
+ stated by Boan et al., not quite in accordance with international stroke guidelines.
993
+ <xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0024"><sup>24</sup></xref></p>
994
+ <p>In a study where patients with minor stroke were randomized to six clinic visits by a
995
+ pharmacist (intervention) or by a nurse (active control) aiming at treating both BP
996
+ and LDL-cholesterol to target, 43% of patients in the pharmacist-led clinic met
997
+ those two targets and so did 31% in the nurse-led clinic. <xref ref-type="bibr"
998
+ rid="BRB3-2019-12-0787-bib-0025"><sup>25</sup></xref> In our study this combined
999
+ endpoint was met in 22 (61%) of patients in the intervention group. Regarding BP in
1000
+ control 80% of patients in the pharmacist led clinic had systolic BP in control
1001
+ after six months versus 90% in the nurse led clinic. This is a far greater
1002
+ proportion than the 69% in our study. However, almost two thirds of patients had a
1003
+ baseline BP within the limits. The opposite was the case in our study with two
1004
+ thirds presenting with elevated BP. Both studies show that a dedicated follow up
1005
+ with stepwise escalation of preventive medication may be the way to reach the
1006
+ targets of the two important risk factors for recurrent stroke. In both studies
1007
+ five-six visits were needed, which is far beyond our usual treatment. However,
1008
+ despite visits to the outpatient clinic as well as to the general practitioner the
1009
+ proportion of patients with unchanged medication since discharge in the control
1010
+ group illustrate the necessity of frequent visits to a dedicated preventive
1011
+ facility. Considering the preventive effect of BP lowering, and - though
1012
+ insignificant - the difference in time to first event as well as the smaller
1013
+ proportion of events in the intervention group as found in our study, it may be well
1014
+ worth the time and resources for patients, their relatives and society.</p>
1015
+ <sec id="BRB3-2019-12-0787-sec4.1">
1016
+ <label>4.1</label>
1017
+ <title>Strengths and limitations</title>
1018
+ <p>Our study has some limitations. Most participants had a minor stroke and patients
1019
+ had to be independent and without severe cognitive deficits, which is not
1020
+ representative of a general stroke population. With only 73 participants caution
1021
+ is called for in the drawing of conclusions from the results. Nonetheless, we
1022
+ decided to reorganize the outpatient clinic of our stroke unit as of October
1023
+ 2014 implementing strategies of the present study.</p>
1024
+ <p>The strength of the study is the individual target for BP taking into account the
1025
+ diagnosis of stroke as well as important comorbidity as recommended by Boan et
1026
+ al. <xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0024"><sup>24</sup></xref>
1027
+ Five-year follow up on vascular complications and death is another important
1028
+ advantage.</p>
1029
+ </sec>
1030
+ </sec>
1031
+ <sec id="BRB3-2019-12-0787-sec5" sec-type="conclusions">
1032
+ <label>5</label>
1033
+ <title>CONCLUSIONS</title>
1034
+ <p>In conclusion, the feasibility study has demonstrated that timely follow up of stroke
1035
+ patients in a dedicated preventive outpatient clinic may result in BP and
1036
+ cholesterol treated to target in most patients. To some extent it may postpone time
1037
+ to stroke recurrence, MI and death.</p>
1038
+ </sec>
1039
+ </body>
1040
+ <back>
1041
+ <ack>
1042
+ <title>ACKNOWLEDGMENTS</title>
1043
+ <p>None.<xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0021"><sup>21</sup></xref></p>
1044
+ </ack>
1045
+ <fn-group>
1046
+ <fn fn-type="conflict">
1047
+ <p content-type="fn-title">CONFLICT OF INTEREST</p>
1048
+ <p>None.</p>
1049
+ </fn>
1050
+ </fn-group>
1051
+ <sec sec-type="data-availability">
1052
+ <title>DATA AVAILABILITY</title>
1053
+ <p>The data that support the findings of this study are not available due to national
1054
+ privacy or ethical restrictions.</p>
1055
+ </sec>
1056
+ <ref-list>
1057
+ <title>Reference List</title>
1058
+ <ref id="BRB3-2019-12-0787-bib-0001">
1059
+ <label>1</label>
1060
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1061
+ ><string-name><surname>Wahlgren</surname>,
1062
+ <given-names>N.</given-names></string-name>,
1063
+ <string-name><surname>Ahmed</surname>,
1064
+ <given-names>N.</given-names></string-name>,
1065
+ <string-name><surname>Eriksson</surname>,
1066
+ <given-names>N.</given-names></string-name>,
1067
+ <string-name><surname>Aichner</surname>,
1068
+ <given-names>F.</given-names></string-name>,
1069
+ <string-name><surname>Bluhmki</surname>,
1070
+ <given-names>E.</given-names></string-name>,
1071
+ <string-name><surname>D&#x00E1;valos</surname>,
1072
+ <given-names>A.</given-names></string-name>, <etal>. . .</etal>
1073
+ <string-name><surname>Vanhooren</surname>,
1074
+ <given-names>G.</given-names></string-name>, &amp; the <collab>Safe
1075
+ Implementation of Thrombolysis in Stroke-MOnitoring STudy
1076
+ Investigators</collab></person-group>. (<year>2008</year>).
1077
+ <article-title>Multivariable analysis of outcome predictors and adjustment
1078
+ of main outcome results to baseline data profile in randomized controlled
1079
+ trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy
1080
+ (SITS-MOST).</article-title>
1081
+ <source>Stroke</source>, <volume>39</volume>,
1082
+ <fpage>3316</fpage>&#x2013;<lpage>3322</lpage>. <pub-id pub-id-type="doi"
1083
+ >https://doi.org/10.1161/STROKEAHA.107.510768</pub-id><pub-id
1084
+ pub-id-type="pmid">18927461</pub-id></mixed-citation>
1085
+ </ref>
1086
+ <ref id="BRB3-2019-12-0787-bib-0002">
1087
+ <label>2</label>
1088
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1089
+ ><string-name><surname>Wahlgren</surname>,
1090
+ <given-names>N.</given-names></string-name></person-group>
1091
+ (<year>2009</year>). <article-title>Systemic thrombolysis in clinical
1092
+ practice: What have we learned after the Safe Implementation of Thrombolysis
1093
+ in Stroke Monitoring Study?</article-title>
1094
+ <source>Cerebrovascular Diseases (Basel, Switzerland)</source>,
1095
+ <volume>27</volume>(<supplement>Suppl 1</supplement>),
1096
+ <fpage>168</fpage>&#x2013;<lpage>176</lpage>. <pub-id pub-id-type="doi"
1097
+ >https://doi.org/10.1159/000200456</pub-id><pub-id pub-id-type="pmid"
1098
+ >19342848</pub-id></mixed-citation>
1099
+ </ref>
1100
+ <ref id="BRB3-2019-12-0787-bib-0003">
1101
+ <label>3</label>
1102
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1103
+ ><string-name><surname>Thorvaldsen</surname>,
1104
+ <given-names>P.</given-names></string-name>,
1105
+ <string-name><surname>Davidsen</surname>,
1106
+ <given-names>M.</given-names></string-name>,
1107
+ <string-name><surname>Br&#x00F8;nnum-Hansen</surname>,
1108
+ <given-names>H.</given-names></string-name>, &amp;
1109
+ <string-name><surname>Schroll</surname>,
1110
+ <given-names>M.</given-names></string-name></person-group>
1111
+ (<year>1999</year>). <article-title>Stable stroke occurrence despite
1112
+ incidence reduction in an aging population: Stroke trends in the danish
1113
+ monitoring trends and determinants in cardiovascular disease (MONICA)
1114
+ population.</article-title>
1115
+ <source>Stroke</source>, <volume>30</volume>,
1116
+ <fpage>2529</fpage>&#x2013;<lpage>2534</lpage>. <pub-id pub-id-type="doi"
1117
+ >https://doi.org/10.1161/01.STR.30.12.2529</pub-id><pub-id
1118
+ pub-id-type="pmid">10582973</pub-id></mixed-citation>
1119
+ </ref>
1120
+ <ref id="BRB3-2019-12-0787-bib-0004">
1121
+ <label>4</label>
1122
+ <?AuthorQuery id="Q4" queryText="eXtyles has not updated the authors because of a name mismatch. Please compare &quot;J&#x00F8;rgensen&quot; with &quot;Jerrgensen&quot;. The CrossRef authors are Jerrgensen, H. S., Nakayama, H., Reith, J., Raaschou, H. O., &amp; Olsen, T. S.. (Ref. 4 &quot;J&#x00F8;rgensen, Nakayama, Reith, Raaschou, Olsen, 1997&quot;)"?>
1123
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1124
+ ><string-name><surname>J&#x00F8;rgensen</surname>, <given-names>H.
1125
+ S.</given-names></string-name>,
1126
+ <string-name><surname>Nakayama</surname>,
1127
+ <given-names>H.</given-names></string-name>,
1128
+ <string-name><surname>Reith</surname>,
1129
+ <given-names>J.</given-names></string-name>,
1130
+ <string-name><surname>Raaschou</surname>, <given-names>H.
1131
+ O.</given-names></string-name>, &amp;
1132
+ <string-name><surname>Olsen</surname>, <given-names>T.
1133
+ S.</given-names></string-name></person-group> (<year>1997</year>).
1134
+ <article-title>Stroke recurrence: Predictors, severity, and prognosis. The
1135
+ Copenhagen Stroke Study.</article-title>
1136
+ <source>Neurology</source>, <volume>48</volume>,
1137
+ <fpage>891</fpage>&#x2013;<lpage>895</lpage>. <pub-id pub-id-type="doi"
1138
+ >https://doi.org/10.1212/WNL.48.4.891</pub-id><pub-id pub-id-type="pmid"
1139
+ >9109873</pub-id></mixed-citation>
1140
+ </ref>
1141
+ <ref id="BRB3-2019-12-0787-bib-0005">
1142
+ <label>5</label>
1143
+ <mixed-citation specific-use="unstructured-citation" publication-type="other">Danish Stroke Registry. Danish Stroke
1144
+ Registry, annual report 2011. 2011. Ref Type: Generic.</mixed-citation>
1145
+ </ref>
1146
+ <ref id="BRB3-2019-12-0787-bib-0006">
1147
+ <label>6</label>
1148
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1149
+ ><string-name><surname>Friday</surname>,
1150
+ <given-names>G.</given-names></string-name>,
1151
+ <string-name><surname>Alter</surname>,
1152
+ <given-names>M.</given-names></string-name>, &amp;
1153
+ <string-name><surname>Lai</surname>, <given-names>S.
1154
+ M.</given-names></string-name></person-group> (<year>2002</year>).
1155
+ <article-title>Control of hypertension and risk of stroke
1156
+ recurrence.</article-title>
1157
+ <source>Stroke</source>, <volume>33</volume>,
1158
+ <fpage>2652</fpage>&#x2013;<lpage>2657</lpage>. <pub-id pub-id-type="doi"
1159
+ >https://doi.org/10.1161/01.STR.0000033929.62136.6F</pub-id><pub-id
1160
+ pub-id-type="pmid">12411656</pub-id></mixed-citation>
1161
+ </ref>
1162
+ <ref id="BRB3-2019-12-0787-bib-0007">
1163
+ <label>7</label>
1164
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1165
+ ><string-name><surname>Lai</surname>, <given-names>S.
1166
+ M.</given-names></string-name>,
1167
+ <string-name><surname>Alter</surname>,
1168
+ <given-names>M.</given-names></string-name>,
1169
+ <string-name><surname>Friday</surname>,
1170
+ <given-names>G.</given-names></string-name>, &amp;
1171
+ <string-name><surname>Sobel</surname>,
1172
+ <given-names>E.</given-names></string-name></person-group>
1173
+ (<year>1994</year>). <article-title>A multifactorial analysis of risk
1174
+ factors for recurrence of ischemic stroke.</article-title>
1175
+ <source>Stroke</source>, <volume>25</volume>,
1176
+ <fpage>958</fpage>&#x2013;<lpage>962</lpage>. <pub-id pub-id-type="doi"
1177
+ >https://doi.org/10.1161/01.STR.25.5.958</pub-id><pub-id pub-id-type="pmid"
1178
+ >8165690</pub-id></mixed-citation>
1179
+ </ref>
1180
+ <ref id="BRB3-2019-12-0787-bib-0008">
1181
+ <label>8</label>
1182
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1183
+ ><string-name><surname>Prencipe</surname>,
1184
+ <given-names>M.</given-names></string-name>,
1185
+ <string-name><surname>Culasso</surname>,
1186
+ <given-names>F.</given-names></string-name>,
1187
+ <string-name><surname>Rasura</surname>,
1188
+ <given-names>M.</given-names></string-name>,
1189
+ <string-name><surname>Anzini</surname>,
1190
+ <given-names>A.</given-names></string-name>,
1191
+ <string-name><surname>Beccia</surname>,
1192
+ <given-names>M.</given-names></string-name>,
1193
+ <string-name><surname>Cao</surname>,
1194
+ <given-names>M.</given-names></string-name>, <etal>. . .</etal>
1195
+ <string-name><surname>Fieschi</surname>,
1196
+ <given-names>C.</given-names></string-name></person-group>
1197
+ (<year>1998</year>). <article-title>Long-term prognosis after a minor
1198
+ stroke: 10-year mortality and major stroke recurrence rates in a
1199
+ hospital-based cohort.</article-title>
1200
+ <source>Stroke</source>, <volume>29</volume>,
1201
+ <fpage>126</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi"
1202
+ >https://doi.org/10.1161/01.STR.29.1.126</pub-id><pub-id pub-id-type="pmid"
1203
+ >9445340</pub-id></mixed-citation>
1204
+ </ref>
1205
+ <ref id="BRB3-2019-12-0787-bib-0009">
1206
+ <label>9</label>
1207
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1208
+ ><string-name><surname>Rashid</surname>,
1209
+ <given-names>P.</given-names></string-name>,
1210
+ <string-name><surname>Leonardi-Bee</surname>,
1211
+ <given-names>J.</given-names></string-name>, &amp;
1212
+ <string-name><surname>Bath</surname>,
1213
+ <given-names>P.</given-names></string-name></person-group>
1214
+ (<year>2003</year>). <article-title>Blood pressure reduction and secondary
1215
+ prevention of stroke and other vascular events: A systematic
1216
+ review.</article-title>
1217
+ <source>Stroke</source>, <volume>34</volume>,
1218
+ <fpage>2741</fpage>&#x2013;<lpage>2748</lpage>. <pub-id pub-id-type="doi"
1219
+ >https://doi.org/10.1161/01.STR.0000092488.40085.15</pub-id><pub-id
1220
+ pub-id-type="pmid">14576382</pub-id></mixed-citation>
1221
+ </ref>
1222
+ <ref id="BRB3-2019-12-0787-bib-0010">
1223
+ <label>10</label>
1224
+ <?AuthorQuery id="Q5" queryText="eXtyles has not updated this reference because the authors returned by CrossRef are invalid: Girot, M., Mackowiak-Cordoliani, M.-A., Deplanque, D., H&#xFFFD;non, H., Lucas, C., &amp; Leys, D. (2005). Secondary prevention after ischemic stroke. Journal of Neurology, <italic>252</italic>, 14&#x2013;20. (Ref. 10 &quot;Girot, Mackowiak-Cordoliani, Deplanque, H&#x00E9;non, Lucas, Leys, 2005&quot;)"?>
1225
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1226
+ ><string-name><surname>Girot</surname>,
1227
+ <given-names>M.</given-names></string-name>,
1228
+ <string-name><surname>Mackowiak-Cordoliani</surname>,
1229
+ <given-names>M. A.</given-names></string-name>,
1230
+ <string-name><surname>Deplanque</surname>,
1231
+ <given-names>D.</given-names></string-name>,
1232
+ <string-name><surname>H&#x00E9;non</surname>,
1233
+ <given-names>H.</given-names></string-name>,
1234
+ <string-name><surname>Lucas</surname>,
1235
+ <given-names>C.</given-names></string-name>, &amp;
1236
+ <string-name><surname>Leys</surname>,
1237
+ <given-names>D.</given-names></string-name></person-group>
1238
+ (<year>2005</year>). <article-title>Secondary prevention after ischemic
1239
+ stroke. Evolution over time in practice.</article-title>
1240
+ <source>Journal of Neurology</source>, <volume>252</volume>,
1241
+ <fpage>14</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi"
1242
+ >https://doi.org/10.1007/s00415-005-0591-8</pub-id><pub-id
1243
+ pub-id-type="pmid">15654550</pub-id></mixed-citation>
1244
+ </ref>
1245
+ <ref id="BRB3-2019-12-0787-bib-0011">
1246
+ <label>11</label>
1247
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1248
+ ><string-name><surname>Johnson</surname>,
1249
+ <given-names>P.</given-names></string-name>,
1250
+ <string-name><surname>Rosewell</surname>,
1251
+ <given-names>M.</given-names></string-name>, &amp;
1252
+ <string-name><surname>James</surname>, <given-names>M.
1253
+ A.</given-names></string-name></person-group> (<year>2007</year>).
1254
+ <article-title>How good is the management of vascular risk after stroke,
1255
+ transient ischaemic attack or carotid endarterectomy?</article-title>
1256
+ <source>Cerebrovascular Diseases (Basel, Switzerland)</source>,
1257
+ <volume>23</volume>, <fpage>156</fpage>&#x2013;<lpage>161</lpage>. <pub-id
1258
+ pub-id-type="doi">https://doi.org/10.1159/000097053</pub-id><pub-id
1259
+ pub-id-type="pmid">17124397</pub-id></mixed-citation>
1260
+ </ref>
1261
+ <ref id="BRB3-2019-12-0787-bib-0012">
1262
+ <label>12</label>
1263
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1264
+ ><string-name><surname>Paul</surname>, <given-names>S.
1265
+ L.</given-names></string-name>, &amp;
1266
+ <string-name><surname>Thrift</surname>, <given-names>A.
1267
+ G.</given-names></string-name></person-group> (<year>2006</year>).
1268
+ <article-title>Control of hypertension 5 years after stroke in the North
1269
+ East Melbourne Stroke Incidence Study.</article-title>
1270
+ <source>Hypertension</source>, <volume>48</volume>,
1271
+ <fpage>260</fpage>&#x2013;<lpage>265</lpage>. <pub-id pub-id-type="doi"
1272
+ >https://doi.org/10.1161/01.HYP.0000230610.81947.04</pub-id><pub-id
1273
+ pub-id-type="pmid">16785330</pub-id></mixed-citation>
1274
+ </ref>
1275
+ <ref id="BRB3-2019-12-0787-bib-0013">
1276
+ <label>13</label>
1277
+ <mixed-citation publication-type="journal">
1278
+ <?AuthorQuery id="Q6" queryText="Medline reports the journal title should be &quot;International journal of stroke : official journal of the International Stroke Society or Int J Stroke&quot;, not &quot;International Journal of Stroke&quot;. (Ref. 13 &quot;Hornnes, Larsen, Boysen, 2010&quot;)"?>
1279
+ <person-group person-group-type="author"
1280
+ ><string-name><surname>Hornnes</surname>,
1281
+ <given-names>N.</given-names></string-name>,
1282
+ <string-name><surname>Larsen</surname>,
1283
+ <given-names>K.</given-names></string-name>, &amp;
1284
+ <string-name><surname>Boysen</surname>,
1285
+ <given-names>G.</given-names></string-name></person-group>
1286
+ (<year>2010</year>). <article-title>Little change of modifiable risk factors
1287
+ 1 year after stroke: A pilot study.</article-title>
1288
+ <source>International Journal of Stroke</source>, <volume>5</volume>,
1289
+ <fpage>157</fpage>&#x2013;<lpage>162</lpage>. <pub-id pub-id-type="doi"
1290
+ >https://doi.org/10.1111/j.1747-4949.2010.00424.x</pub-id><pub-id
1291
+ pub-id-type="pmid">20536611</pub-id></mixed-citation>
1292
+ </ref>
1293
+ <ref id="BRB3-2019-12-0787-bib-0014">
1294
+ <label>14</label>
1295
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1296
+ ><string-name><surname>Adie</surname>,
1297
+ <given-names>K.</given-names></string-name>, &amp;
1298
+ <string-name><surname>James</surname>, <given-names>M.
1299
+ A.</given-names></string-name></person-group> (<year>2010</year>).
1300
+ <article-title>Does telephone follow-up improve blood pressure after minor
1301
+ stroke or TIA?</article-title>
1302
+ <source>Age and Ageing</source>, <volume>39</volume>,
1303
+ <fpage>598</fpage>&#x2013;<lpage>603</lpage>. <pub-id pub-id-type="doi"
1304
+ >https://doi.org/10.1093/ageing/afq085</pub-id><pub-id pub-id-type="pmid"
1305
+ >20667838</pub-id></mixed-citation>
1306
+ </ref>
1307
+ <ref id="BRB3-2019-12-0787-bib-0015">
1308
+ <label>15</label>
1309
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1310
+ ><string-name><surname>Chiu</surname>, <given-names>C.
1311
+ C.</given-names></string-name>, <string-name><surname>Wu</surname>,
1312
+ <given-names>S. S.</given-names></string-name>,
1313
+ <string-name><surname>Lee</surname>, <given-names>P.
1314
+ Y.</given-names></string-name>,
1315
+ <string-name><surname>Huang</surname>, <given-names>Y.
1316
+ C.</given-names></string-name>, <string-name><surname>Tan</surname>,
1317
+ <given-names>T. Y.</given-names></string-name>, &amp;
1318
+ <string-name><surname>Chang</surname>, <given-names>K.
1319
+ C.</given-names></string-name></person-group> (<year>2008</year>).
1320
+ <article-title>Control of modifiable risk factors in ischemic stroke
1321
+ outpatients by pharmacist intervention: An equal allocation stratified
1322
+ randomized study.</article-title>
1323
+ <source>Journal of Clinical Pharmacy and Therapeutics</source>,
1324
+ <volume>33</volume>, <fpage>529</fpage>&#x2013;<lpage>535</lpage>. <pub-id
1325
+ pub-id-type="doi"
1326
+ >https://doi.org/10.1111/j.1365-2710.2008.00940.x</pub-id><pub-id
1327
+ pub-id-type="pmid">18834368</pub-id></mixed-citation>
1328
+ </ref>
1329
+ <ref id="BRB3-2019-12-0787-bib-0016">
1330
+ <label>16</label>
1331
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1332
+ ><string-name><surname>Ellis</surname>,
1333
+ <given-names>G.</given-names></string-name>,
1334
+ <string-name><surname>Rodger</surname>,
1335
+ <given-names>J.</given-names></string-name>,
1336
+ <string-name><surname>McAlpine</surname>,
1337
+ <given-names>C.</given-names></string-name>, &amp;
1338
+ <string-name><surname>Langhorne</surname>,
1339
+ <given-names>P.</given-names></string-name></person-group>
1340
+ (<year>2005</year>). <article-title>The impact of stroke nurse specialist
1341
+ input on risk factor modification: A randomised controlled
1342
+ trial.</article-title>
1343
+ <source>Age and Ageing</source>, <volume>34</volume>,
1344
+ <fpage>389</fpage>&#x2013;<lpage>392</lpage>. <pub-id pub-id-type="doi"
1345
+ >https://doi.org/10.1093/ageing/afi075</pub-id><pub-id pub-id-type="pmid"
1346
+ >15955759</pub-id></mixed-citation>
1347
+ </ref>
1348
+ <ref id="BRB3-2019-12-0787-bib-0017">
1349
+ <label>17</label>
1350
+ <?AuthorQuery id="Q7" queryText="Medline reports the journal title should be &quot;Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association or J Stroke Cerebrovasc Dis&quot;, not &quot;Journal of Stroke and Cerebrovascular Diseases&quot;. (Ref. 17 &quot;Hornnes, Larsen, Boysen, 2011&quot;)"?>
1351
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1352
+ ><string-name><surname>Hornnes</surname>,
1353
+ <given-names>N.</given-names></string-name>,
1354
+ <string-name><surname>Larsen</surname>,
1355
+ <given-names>K.</given-names></string-name>, &amp;
1356
+ <string-name><surname>Boysen</surname>,
1357
+ <given-names>G.</given-names></string-name></person-group>
1358
+ (<year>2011</year>). <article-title>Blood pressure 1 year after stroke: The
1359
+ need to optimize secondary prevention.</article-title>
1360
+ <source>Journal of Stroke and Cerebrovascular Diseases</source>,
1361
+ <volume>20</volume>, <fpage>16</fpage>&#x2013;<lpage>23</lpage>. <pub-id
1362
+ pub-id-type="doi"
1363
+ >https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.10.002</pub-id><pub-id
1364
+ pub-id-type="pmid">21187254</pub-id></mixed-citation>
1365
+ </ref>
1366
+ <ref id="BRB3-2019-12-0787-bib-0018">
1367
+ <label>18</label>
1368
+ <?AuthorQuery id="Q8" queryText="CrossRef reports the first page should be &quot;NA&quot;, not &quot;579&quot;. (Ref. 18 &quot;Johnston, Sidney, Hills, Grosvenor, Klingman, Bernstein, Levin, 2010&quot;)"?>
1369
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1370
+ ><string-name><surname>Johnston</surname>, <given-names>S.
1371
+ C.</given-names></string-name>,
1372
+ <string-name><surname>Sidney</surname>,
1373
+ <given-names>S.</given-names></string-name>,
1374
+ <string-name><surname>Hills</surname>, <given-names>N.
1375
+ K.</given-names></string-name>,
1376
+ <string-name><surname>Grosvenor</surname>,
1377
+ <given-names>D.</given-names></string-name>,
1378
+ <string-name><surname>Klingman</surname>, <given-names>J.
1379
+ G.</given-names></string-name>,
1380
+ <string-name><surname>Bernstein</surname>,
1381
+ <given-names>A.</given-names></string-name>, &amp;
1382
+ <string-name><surname>Levin</surname>,
1383
+ <given-names>E.</given-names></string-name></person-group>
1384
+ (<year>2010</year>). <article-title>Standardized discharge orders after
1385
+ stroke: Results of the quality improvement in stroke prevention (QUISP)
1386
+ cluster randomized trial.</article-title>
1387
+ <source>Annals of Neurology</source>, <volume>67</volume>,
1388
+ <fpage>579</fpage>&#x2013;<lpage>589</lpage>. <pub-id pub-id-type="doi"
1389
+ >https://doi.org/10.1002/ana.22019</pub-id><pub-id pub-id-type="pmid"
1390
+ >20437555</pub-id></mixed-citation>
1391
+ </ref>
1392
+ <ref id="BRB3-2019-12-0787-bib-0019">
1393
+ <label>19</label>
1394
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1395
+ ><string-name><surname>Joubert</surname>,
1396
+ <given-names>J.</given-names></string-name>,
1397
+ <string-name><surname>Reid</surname>,
1398
+ <given-names>C.</given-names></string-name>,
1399
+ <string-name><surname>Barton</surname>,
1400
+ <given-names>D.</given-names></string-name>,
1401
+ <string-name><surname>Cumming</surname>,
1402
+ <given-names>T.</given-names></string-name>,
1403
+ <string-name><surname>McLean</surname>,
1404
+ <given-names>A.</given-names></string-name>,
1405
+ <string-name><surname>Joubert</surname>,
1406
+ <given-names>L.</given-names></string-name>, <etal>. . .</etal>
1407
+ <string-name><surname>Davis</surname>,
1408
+ <given-names>S.</given-names></string-name></person-group>
1409
+ (<year>2009</year>). <article-title>Integrated care improves risk-factor
1410
+ modification after stroke: Initial results of the Integrated Care for the
1411
+ Reduction of Secondary Stroke model.</article-title>
1412
+ <source>Journal of Neurology, Neurosurgery, and Psychiatry</source>,
1413
+ <volume>80</volume>, <fpage>279</fpage>&#x2013;<lpage>284</lpage>. <pub-id
1414
+ pub-id-type="doi">https://doi.org/10.1136/jnnp.2008.148122</pub-id><pub-id
1415
+ pub-id-type="pmid">19010943</pub-id></mixed-citation>
1416
+ </ref>
1417
+ <ref id="BRB3-2019-12-0787-bib-0020">
1418
+ <label>20</label>
1419
+ <?AuthorQuery id="Q9" queryText="Medline reports multiple listings for this reference. Please check the reference for accuracy. (Ref. 20 &quot;Fahey, Schroeder, Ebrahim, 2006&quot;)"?>
1420
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1421
+ ><string-name><surname>Fahey</surname>,
1422
+ <given-names>T.</given-names></string-name>,
1423
+ <string-name><surname>Schroeder</surname>,
1424
+ <given-names>K.</given-names></string-name>, &amp;
1425
+ <string-name><surname>Ebrahim</surname>,
1426
+ <given-names>S.</given-names></string-name></person-group>
1427
+ (<year>2006</year>). <article-title>Interventions used to improve control of
1428
+ blood pressure in patients with hypertension.</article-title>
1429
+ <source>Cochrane Database of Systematic Reviews</source>,
1430
+ <elocation-id>CD005182</elocation-id>.</mixed-citation>
1431
+ </ref>
1432
+ <ref id="BRB3-2019-12-0787-bib-0021">
1433
+ <label>21</label>
1434
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1435
+ ><string-name><surname>Furie</surname>, <given-names>K.
1436
+ L.</given-names></string-name>,
1437
+ <string-name><surname>Kasner</surname>, <given-names>S.
1438
+ E.</given-names></string-name>,
1439
+ <string-name><surname>Adams</surname>, <given-names>R.
1440
+ J.</given-names></string-name>,
1441
+ <string-name><surname>Albers</surname>, <given-names>G.
1442
+ W.</given-names></string-name>,
1443
+ <string-name><surname>Bush</surname>, <given-names>R.
1444
+ L.</given-names></string-name>, <string-name><surname>Fagan</surname>,
1445
+ <given-names>S. C.</given-names></string-name>, <etal>. . .</etal>
1446
+ <string-name><surname>Wentworth</surname>,
1447
+ <given-names>D.</given-names></string-name>, &amp; the <collab>American
1448
+ Heart Association Stroke Council, Council on Cardiovascular Nursing,
1449
+ Council on Clinical Cardiology, and Interdisciplinary Council on Quality
1450
+ of Care and Outcomes Research</collab></person-group>.
1451
+ (<year>2011</year>). <article-title>Guidelines for the prevention of stroke
1452
+ in patients with stroke or transient ischemic attack: A guideline for
1453
+ healthcare professionals from the american heart association/american stroke
1454
+ association.</article-title>
1455
+ <source><italic>Stroke</italic></source>, <volume>42</volume>,
1456
+ <fpage>227</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi"
1457
+ >https://doi.org/10.1161/STR.0b013e3181f7d043</pub-id><pub-id
1458
+ pub-id-type="pmid">20966421</pub-id></mixed-citation>
1459
+ </ref>
1460
+ <ref id="BRB3-2019-12-0787-bib-0022">
1461
+ <label>22</label>
1462
+ <?AuthorQuery id="Q10" queryText="Medline reports the journal title should be &quot;The Cochrane database of systematic reviews or Cochrane Database Syst Rev&quot;, not &quot;Cochrane Database of Systematic Reviews&quot;. (Ref. 22 &quot;Bridgwood, Lager, Mistri, Khunti, Wilson, Modi, 2018&quot;)"?>
1463
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1464
+ ><string-name><surname>Bridgwood</surname>,
1465
+ <given-names>B.</given-names></string-name>,
1466
+ <string-name><surname>Lager</surname>, <given-names>K.
1467
+ E.</given-names></string-name>,
1468
+ <string-name><surname>Mistri</surname>, <given-names>A.
1469
+ K.</given-names></string-name>,
1470
+ <string-name><surname>Khunti</surname>,
1471
+ <given-names>K.</given-names></string-name>,
1472
+ <string-name><surname>Wilson</surname>, <given-names>A.
1473
+ D.</given-names></string-name>, &amp;
1474
+ <string-name><surname>Modi</surname>,
1475
+ <given-names>P.</given-names></string-name></person-group>
1476
+ (<year>2018</year>). <article-title>Interventions for improving modifiable
1477
+ risk factor control in the secondary prevention of stroke.</article-title>
1478
+ <source>Cochrane Database of Systematic Reviews</source>, <volume>5</volume>,
1479
+ <elocation-id>CD009103</elocation-id>.<pub-id pub-id-type="pmid"
1480
+ >29734470</pub-id></mixed-citation>
1481
+ </ref>
1482
+ <ref id="BRB3-2019-12-0787-bib-0023">
1483
+ <label>23</label>
1484
+ <?AuthorQuery id="Q11" queryText="CrossRef reports the title is &quot;2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)&quot;. (Ref. 23 &quot;Mancia, Fagard, Narkiewicz, Red&#x00E1;n, Zanchetti, B&#x00F6;hm, Zannad, . . ., 2013&quot;)"?>
1485
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1486
+ ><string-name><surname>Mancia</surname>,
1487
+ <given-names>G.</given-names></string-name>,
1488
+ <string-name><surname>Fagard</surname>,
1489
+ <given-names>R.</given-names></string-name>,
1490
+ <string-name><surname>Narkiewicz</surname>,
1491
+ <given-names>K.</given-names></string-name>,
1492
+ <string-name><surname>Red&#x00E1;n</surname>,
1493
+ <given-names>J.</given-names></string-name>,
1494
+ <string-name><surname>Zanchetti</surname>,
1495
+ <given-names>A.</given-names></string-name>,
1496
+ <string-name><surname>B&#x00F6;hm</surname>,
1497
+ <given-names>M.</given-names></string-name>, <etal>. . .</etal>
1498
+ <string-name><surname>Zannad</surname>,
1499
+ <given-names>F.</given-names></string-name>, &amp; the <collab>ESH/ESC
1500
+ Task Force for the Management of Arterial
1501
+ Hypertension</collab></person-group>. (<year>2013</year>).
1502
+ <article-title>2013 Practice guidelines for the management of arterial
1503
+ hypertension of the <italic>European</italic> Society of Hypertension (ESH) and the European
1504
+ Society of Cardiology (ESC): ESH/ESC Task Force for the Management of
1505
+ Arterial Hypertension.</article-title>
1506
+ <source>Journal of Hypertension</source>, <volume>31</volume>,
1507
+ <fpage>1925</fpage>&#x2013;<lpage>1938</lpage>. <pub-id pub-id-type="doi"
1508
+ >https://doi.org/10.1097/HJH.0b013e328364ca4c</pub-id><pub-id
1509
+ pub-id-type="pmid">24107724</pub-id></mixed-citation>
1510
+ </ref>
1511
+ <ref id="BRB3-2019-12-0787-bib-0024">
1512
+ <label>24</label>
1513
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1514
+ ><string-name><surname>Boan</surname>, <given-names>A.
1515
+ D.</given-names></string-name>,
1516
+ <string-name><surname>Lackland</surname>, <given-names>D.
1517
+ T.</given-names></string-name>, &amp;
1518
+ <string-name><surname>Ovbiagele</surname>,
1519
+ <given-names>B.</given-names></string-name></person-group>
1520
+ (<year>2014</year>). <article-title>Lowering of blood pressure for recurrent
1521
+ stroke prevention.</article-title>
1522
+ <source>Stroke</source>, <volume>45</volume>,
1523
+ <fpage>2506</fpage>&#x2013;<lpage>2513</lpage>. <pub-id pub-id-type="doi"
1524
+ >https://doi.org/10.1161/STROKEAHA.114.003666</pub-id><pub-id
1525
+ pub-id-type="pmid">24984744</pub-id></mixed-citation>
1526
+ </ref>
1527
+ <ref id="BRB3-2019-12-0787-bib-0025">
1528
+ <label>25</label>
1529
+ <?AuthorQuery id="Q12" queryText="Medline reports the journal title should be &quot;CMAJ : Canadian Medical Association journal = journal de l&#x2019;Association medicale canadienne or CMAJ&quot;, not &quot;Canadian Medical Association Journal&quot;. (Ref. 25 &quot;McAlister, Majumdar, Padwal, Fradette, Thompson, Buck, Shuaib, . . ., 2014&quot;)"?>
1530
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1531
+ ><string-name><surname>McAlister</surname>, <given-names>F.
1532
+ A.</given-names></string-name>,
1533
+ <string-name><surname>Majumdar</surname>, <given-names>S.
1534
+ R.</given-names></string-name>,
1535
+ <string-name><surname>Padwal</surname>, <given-names>R.
1536
+ S.</given-names></string-name>,
1537
+ <string-name><surname>Fradette</surname>,
1538
+ <given-names>M.</given-names></string-name>,
1539
+ <string-name><surname>Thompson</surname>,
1540
+ <given-names>A.</given-names></string-name>,
1541
+ <string-name><surname>Buck</surname>,
1542
+ <given-names>B.</given-names></string-name>, <etal>. . .</etal>
1543
+ <string-name><surname>Shuaib</surname>,
1544
+ <given-names>A.</given-names></string-name></person-group>
1545
+ (<year>2014</year>). <article-title>Case management for blood pressure and
1546
+ lipid level control after minor stroke: PREVENTION randomized controlled
1547
+ trial.</article-title>
1548
+ <source>Canadian Medical Association Journal</source>, <volume>186</volume>,
1549
+ <fpage>577</fpage>&#x2013;<lpage>584</lpage>. <pub-id pub-id-type="doi"
1550
+ >https://doi.org/10.1503/cmaj.140053</pub-id><pub-id pub-id-type="pmid"
1551
+ >24733770</pub-id></mixed-citation>
1552
+ </ref>
1553
+ </ref-list>
1554
+ </back>
1555
+ <floats-group>
1556
+ <graphic content-type="leading" xlink:href="fig1.png">
1557
+ <alt-text>example of alt text for hero-image</alt-text>
1558
+ <long-desc>example of long desc for hero image</long-desc>
1559
+ </graphic>
1560
+ </floats-group>
1561
+ </article>